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Abstract
A novel device for the testing of medicinal aerosols has been developed. Devices exist which can 
quantify the potentially respirable particles within an aerosol cloud, these generally have not been 
produced to mimic the physiological conditions of the lung or predict lung deposition patterns. 
The novel device, the Shell Model Lung (SML) has been developed as a novel in vitro device that 
aims to provide a correlation between the in vitro and in vivo analysis of medicinal aerosols 
intended for pulmonary administration.
The SML design was based on the hemispherical transformation of the human lung incorporating 
data taken from the Weibel model of the human lung. Data from the Weibel model was used to 
construct the interior network of holes representing the airways of the human lung in the five 
shells.
A two-dimensional physical model (2DSML) has been developed along with a computational 
fluid dynamics model. This has enabled pressure measurements to be taken throughout the 
2DSML by encasing it within two Perspex sheets. Fluid visualisation studies of the device were 
performed to assess the flow response to streak and bolus injections of coloured dye into the 
model.
The model has undergone a calibration at AEA (Culham) using monodisperse particles. The 
calibration has demonstrated that the model collects particles by more than one mechanism. The 
results have shown that the SML is capable of separating an aerosol cloud. The theoretical cut 
point and the experimentally determined cut point at Shell 1 are in good agreement. The model 
has been tested using commercially available metered dose and dry powder inhalers. Factors 
involved in the separation of aerosol clouds have been investigated such as altering the flow rate 
through the device. The commercially available inhalers used during the study have been 
assessed using an Andersen Cascade Impactor.
Recommendations for further work have been made including the overall improvement of the 
design, introducing an anatomical throat, improving flow conditions and increasing the surface 
for deposition.
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Chapter 1 General Introduction
1.1 Lung Physiology
The total surface area of a human lung is in the order of 40 to 80m . The lung 
contains approximately 300 million alveoli, which make up around 90% of the total 
absorption surface available in the lung. The lungs are separated into lobes; the right 
lung is made up of three and the left two lobes. These lobes are further divided into 
bronchopulmonary segments; each segment receives its own segmental bronchus, 
which consists of lobules of around 1 cm in diameter these are generally pyramidal in 
shape (Weibel and Gomez, 1962). Within each lobule a terminal bronchus supplies 
an acinus, a complex of alveolated airways distal to the terminal bronchioles that is, 
beginning with the first order respiratory or ‘transitional* bronchioles (Haefeli-Bleuer 
and Weibel, 1988). Within this structure further divisions of the bronchiole 
eventually give rise to the alveoli. The upper airways can be considered as 
conducting and conditioning ducts and the lower regions, especially the alveoli as 
tissues for the exchange of gasses. The lung is a complex structure its primary 
function is the exchange of gasses between air and blood. The huge surface area 
required for this purpose is achieved by the branching ‘tree-like’ structure. The 
branching generally occurs in a regular pattern (Weibel, 1991).
1.2 Local Treatments to the lung
Diseases of the lung can be targeted directly by the application of drugs onto the lung 
tissue thus avoiding first pass metabolism and reducing side effects in die patient.
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Bronchodilators: act on the smooth muscle in the lung to reverse the constriction of 
the airway. Clinical effect is better when they are dispersed throughout the lower 
respiratory tract (Newhouse, 1998). Therefore aerosols of (3 receptor agonists 
containing small particles are more effective. The drug will act on the lung in the 
same way irrespective of the cause on constriction (Rang and Dale, 1994).
Examples: salbutamol, terbutaline. Salmeterol is a long acting drug of the same class.
Muscarinic receptor antagonists: are used to treat reflex muscle spasms caused by 
the parasympathetic nervous system receptors are located in the Bronchi (Newhouse, 
1998).
Examples: Ipratropium Bromide, Oxitropium.
Glucocorticoids: inhibit inflammatory mediators.
Examples: Beclomethasone, Fluticasone, Budesonide
Sodium Cromoglycate / Nedocromil Sodium: the mechanism is unclear but it is 
thought to stabilise the cells, which release the inflammatory mediators, and 
suppresses other types of inflammatory cells.
Antibiotics and antiviral agents
In conditions where bacteria or viruses may easily colonise the lung to produce 
infections such as cystic fibrosis (CF) or acquired immunodeficiency syndrome 
(AIDS), it may be necessary to administer drugs directly to the lung tissue. 
Pseudomonas aeruginosa or Staphylococcus aureus commonly causes infections 
associated with CF. Aerosolised antibiotics deliver a large concentration directly to
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the site of the infection. If the antibiotic is administered systemically very high doses 
are required to create a therapeutic level in the sputum. A high incidence of side 
effects associated with aminoglycosides when taken orally prevent their routine use 
however, when presented as an aerosol formulation they become more acceptable. 
Pentamidine: used to treat infections caused by the protozoan Pneumosystic carinii, a 
cause of pneumonia to which AIDS patients are susceptible.
1.3 Protein delivery to the lung for systemic effects
The systemic pharmacological response by aerosolised insulin delivered to the lung 
was first reported in 1971 by Wigley (Wigley et al., 1971). For aerosols to have a 
systemic effect, they must reach the alveoli and become absorbed into the 
bloodstream. It is difficult for proteins to be delivered orally as the enzymes present 
in the stomach break down and deactivate proteins.
For a macromolecule such as insulin to cross the air/ blood barrier that is the lung 
tissue it has to cross several layers. The first barrier is the lung surfactant, a single 
molecular monolayer lining the tissues of the pulmonary tract. Under the surfactant is 
a layer of surface lining fluid in the conducting airways it contains mucus and is 
moved by ciliary activity to the trachea. The surface lining fluid at the alveolar level 
is thinner and no cilia are present in these tissues. The macromolecule has to get 
through the surfactant layer and dissolve in the surface lining fluid before it can get to 
the epithelial cells. Macromolecular absorption occurs as a natural process.
(Johnson, 1997)
• Absorptive transcytosis -  through cell absorption,
• Paracellular transport -  between cell absorption.
These routes through the epithelial layer lead the molecule to the interstitium and 
basement membrane of the lung tissue these structures hold the epithelium in its 
conformation. They appear to not hinder the progress of the macromolecule. Once 
through the cells of the lung the macromolecule diffuses through the vascular 
epithelium and into the blood stream (Patton, 1996).
It is thought that an insulin formulation must have a dae in the region of 1 - 3 pm to 
reach its site of absorption (Patton, 1997). There are significant formulation problems 
when dealing with proteins and peptides. The complex structure of proteins makes 
them particularly unstable. Changes in their secondary, tertiary or quaternary 
structure can alter or destroy their potency. It is very easy to denature the physical 
structure of proteins; heating, cooling, pH changes and shear can change these 
physical characteristics. Various methods of incurring stability on proteins may be 
used during formulation. Excluding water from, adding excipients such as sugars, 
polyols, surfactants or polymers to the protein structure will enhance the physical 
stability of the molecule (Parkins and Lashmar, 2000).
1.4 Particle size
In order for the drug particles to reach their site of action they generally have a size in 
the range of 2 to 5pm. An ideal aerosol will contain particles of exactly the same 
shape and size this is termed a monodisperse aerosol. In reality, the particles in a 
typical pharmaceutical aerosol cloud are polydisperse, this means their aerodynamic 
diameter varies from around 0.5pm to more than 12pm. The size distribution of the
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polydisperse particles in pulmonary aerosols generally approximate to a lognormal 
size function.
The geometric standard deviation og is a measure of the aerosol size polydispersity. A 
monodisperse population would have a a g = 1. It is impossible to prepare a medicinal 
aerosol, which is monodisperse, so cg~ 1 .2  is conventionally set as the limit at which 
polydispersity starts.
The drug particles in an aerosol are not the same shape; the size of a particle is said to 
be a function of its aerodynamic diameter, dae.
The dae is defined as the diameter of a sphere of unit density, which has the same 
terminal settling velocity as the particle in question.
The mass median aerodynamic diameter (MMAD) is the aerodynamic size of the 
particles below or above which 50% of the drug particles reside. When any new drug 
and or formulation for pulmonary administration are assessed the aerosol is tested for 
its drug content and also the aerodynamic diameter of the particles present in the 
aerosol cloud. The dae of an aerosol is thought to influence the lung deposition pattern 
that will be seen.
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1.5 Impactor Theory
Collection of particles by impaction exploits a particle’s inability to follow a curved 
path. The principle of collecting particles by impaction is sound and used routinely. 
A vertical jet o f a given diameter is directed at a horizontal plate as particles travel 
through the jet at a given velocity the inertia imparted on them will determine if  they 
can negate the 90° ‘bend’ and avoid a collision with the plate. Figure 1.1 is a 
schematic cross sectional diagram o f an impactor, particles with high momentum will 
not follow the airflow and so impact on the collecting surface. It is possible for 
smaller particles to continue in the path of the airflow and move through the stage of 
the impaction device.





Particle ‘a’ has been collected on the impaction plate, as its momentum cannot be 
overcome by the direction of the airflow around the plate. Particle ‘b’ has less
6
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momentum and so remains in the airflow and will be carried to the next impaction 
stage where the airflow will be increased and the particle given a higher momentum.
For a given plate there is said to be a cut point (units = metres) above which, particles 
will be collected i.e. impact on the plate or be collected on a previous collecting 
surface. A cut point should be as sharp as possible for the user to be confident of the 
results an impaction device produces. The measure of the ‘sharpness’ of a cut point is 
called the efficiency curve. An efficiency curve will be constructed for each plate or 
collecting surface using theoretical or calibration data.
The Stokes Number, Stk for an impactor is defined as the ratio of the particles 
stopping distance at the average jet exit velocity U to the jet radius (or half width for a 
rectangular nozzle) r.
Theoretical determinations of a cut point would involve solving the Navier-Stokes 
equation for each jet’s geometry. For routine calibration of instruments an aerosol 
with monodisperse particles of known diameters is used and the results are plotted as 
collection efficiency (% of the total collection for the collecting surface in question of 
the whole impactor at the relevant particle size) against particle size. Figure 1.2 
shows a collection efficiency curve examples of this type of graph can be seen in 
chapter 4.
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1.6 In vitro Testing of Medicinal Aerosols
It is generally accepted that a drug contained in a pharmaceutical aerosol must reach a 
specific area o f the pulmonary environment to have its effect.
A number o f in vitro test methods for medical aerosols have been developed. These 
devices are intended to aid the formulation development and quality control of such 
systems. The testing devices available to us are purely analytical and although they 
accurately describe the aerosol cloud sizing characteristics, they cannot predict the 
region of the lung in which the aerosol will deposit.
I.6.1 The Andersen Cascade Impactor
The Andersen Sampler was first designed for assessing microbiological particles in 
the air (Andersen, 1956). Andersen set out to produce a device, which could be used 
to collect, count and size viable airborne particles. The model was later developed 
into a cascade impactor for the aerodynamic sizing of both liquid and solid non-viable 
particles. The Mark I impactor was launched in 1970 and covers a range of 0.4pm to
I I .0pm. The Mark II impactor most commonly used today was released in 1977 it 
had been redesigned to reduce particle bounce and minimise wall-losses. This device 
now appears as standard testing equipment for medical aerosols in the USP. The 
Andersen Cascade Impactor (ACI) is probably the most comprehensive aerosol 
separator available it fractionates the aerosol into 8  size ranges from 10 to 0.43pm. 
Particles larger than 10pm are retained in a preseparator, eight further stages 
providing 50% cut-off diameters of 9.0, 5.8,4.7, 3.3,2.1,1.1, 0.7 and 0.4pm, and a 
final filter. This impactor operates at a flow rate of 28.3 L min' 1 (Graseby-Andersen, 
1985). A preseparator may be placed above stage 0 in order to remove any particles 
above 1 0 .0 pm from the aerosol cloud.
Using impactor theory, Stein (1999) describes how much individual ACI’s vary in 
their cut-points. The jet diameters of three ACI’s were measured and theoretical cut- 
points were determined based on the data. The ACI’s used were well within the 
manufacturers size specification range. On testing three MDI formulations in the three 
pre-determined ACI’s it was found that measurements for each MDI on a given ACI 
appeared very consistent. Variations between ACI’s for the same MDI formulation 
were large. It is therefore important to use these instruments with care and it may be 
necessary to take into consideration any additional calibration data made available.
9
The jet dimensions (ideal) of an ACI range from 0.0994” to 0.00095". The process of 
making such small holes however well regulated will contain some error. When 
trying to distinguish between particle sizes of maybe less than 0 .1 pm this error may 
become significant in a characterisation of an aerosol cloud.
Impactors are generally used to test metered dose inhalers however, it is possible to 
make several modifications to the operation of the ACI for the testing of dry powder 
inhalers. The “new” ACI (Mark II, 8  stage ACI) has an extra stage inserted (stage -1) 
above stage 0 which allows the ACI to be operated at 601 min' 1 and retain the 
capability to achieve a cut-point at 9.0pm. Without this extra stage the first cut-point 
would be 8 .6 pm, thus reducing the range of fractionation. The operation of the ACI 
at a flow rate of 60 1 min' 1 is necessary if dry powder inhalers are to be tested using 
this apparatus (Nichols et a l)  creating the necessary pressure drop of 4kPa over the 
device (Byron, 1997). A further modification of the ACI has been described by 
Nichols and Smurthwaite (1998), stage 7 has been removed as its cut-point is of little 
value and stage -0 added to allow stage -1 to be fitted. ACI plates are made of 
aluminium therefore it is sometimes necessary to coat the plates. When using dry 
particles (Rao and Whitby) or low numbers of liquid particles, “single puff” 
determinations (Nasr et a l) it has been advised to apply a sticky layer to the plate. 
Coating the plates prevents the bouncing of particles off the surface, wall loss, blow- 
off, de-agglomeration and re-entraining in the ACI. Coating of the plates may be 
achieved using for example, silicone, grease or glycerine.
The characterisation of an aerosol generated by nebulisation has caused some 
difficulty. After around 6  minutes of operation four nebulisers tested had an aerosol
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output temperature of between 5°C and 14°C (Phipps and Gonda). Stapleton and 
Finlay (1998) reported a MMAD error between the operation of the ACI at ambient 
and cooled (10°C) temperature was 52%. It was suggested that the nebulisers could 
be heated to room temperature but this may change any one of the aerosols physical 
properties.
1.6.2 The Marple- Miller Impactor (MMI)
This impactor has five stages plus a final filter. The particle cut-off diameters are 
10.0, 5.0, 2.5, 1.25 and 0.625pm. Calibration data for this impactor are available for 
operation at 30 or 60 1 min"1. There is no method of preseparation of the aerosol in 
this apparatus and it does not completely disassemble after each analysis, which is a 
disadvantage as there may be some loss of the drug within the impactor particularly 
with some DPI devices (Olsson, Asking and Johansson, 1998). The high cost of this 
instrument has also been cited as a reason for its relatively narrow use (Marple et al., 
1995). In 1998 Olson et al developed a low-flow version of the MMI. A low flow 
rate impactor would be particularly useful when investigating the deposition of an 
aerosol in a child or when a low-inhalation flow rate is recommended to a patient.
The flow rates designated were 4.9 and 12 litre min"1. To achieve a comprehensive 
range of cut-points the MMI was modified for use at the low flow rates. The jet 
nozzle diameter at each stage was altered according to impaction theory to provide the 
necessary cut-point. A reported <5% inter-stage drug loss within the impactor is in 
line with the USP recommendations.
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1.6.3 Single Stage Impactor
The impactor described as Apparatus B, (BP) or Single stage Impactor no.2 (U.S.P.) 
is constructed from aluminium. The impactor has a cut-off diameter of 9.8 pm (which 
is well outside the respirable range). Furthermore the particles impact onto a solid 
plate and thus, if they are solid and dry they may bounce off the plate unless the plate 
is sufficiently coated. The TSI and Apparatus B generally operate at a flow rate of 
601 m in 1 unless otherwise calibrated at different flow rates.
1.6.4 The Twin Stage Impinger (TSI)
The TSI is also known as Apparatus A, B.P., or Single Stage Impactor no.3, U.S.P. A 
TSI is made of glass it divides the aerosol into two size fractions, particles above and 
below a cutpointof 6.4pm, although jet modifications can be made which allow other 
size fractions to be analysed. The TSI does not give adequate data on the range of 
particle sizes present in the aerosol cloud but it is a quick method and good for 
screening.
1.6.5 The Multi-Stage Liquid Impinger (MSLI)
The MSLI is particularly suitable for testing dry powder inhalers. Drug particles are 
collected on a liquid surface that has a high capacity for powder retention (Asking and 
Olsson, 1997). There are four stages plus a filter stage; which can give an adequate 
analysis of an aerosol. The MSLI has been calibrated at various flow rates (30 to 100 1 
min'1) and has a lower loss of drug on its walls than the Anderson or the Marple- 
Miller impactor (Olsson et al., 1998) however; the analysis of the MSLI is difficult 
and time consuming.
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These instruments generally characterise the aerosol cloud with reasonable accuracy 
and calibration data are available for all however, they do not accurately predict how 
the drug particles will be distributed in the lung. In general the guiding principles in 
their design have been ease and accuracy of analysis rather than an attempt to closely 
mimic the physiological situation pertaining in the healthy or diseased lung.
1.6.6 NGI -  the Next Generation Impactor
The NGI was designed specifically for pharmaceutical aerosol testing. Its design was 
drawn from a series of requirements set in place by a consortium made up of 
European Industrial scientists (Wright and Shrubb, 1998). The NGI has many 
advantages over the devices described above.
As it was designed specifically to test particles for inhalation it operates and is 
calibrated over a wide range of flow rates (30 to 1001 min'1). The cut points 
throughout the device over the flow rate range were designed to give suitable 
information around the region of interest.
The impactor uses a USP throat as an entry port. Each collection stage is a ‘cup* 
rather than a flat plate this enables the collection stages to be coated if appropriate and 
allows larger quantities of drug to be deposited than a flat plate would. The collection 
cups and low wall losses allow for a quick turnaround as the cups may be removed for 
analysis and clean cups immediately replaced. The NGI has an absolute filter at the 
exit.
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Although the NGI appears to have many advantages over the other devices described 
it still gives no information on in vivo performance of aerosols. The impactors by 
definition collect particles by impaction however this is not the only method of 
particle deposition in the lung.
The analytical instruments used for aerosols testing were briefly compared:
Figure 1.3 Comparison of impactors and impingers currently available.
Device Quick? Easy to analyse? Good separation? Good Preseparation?
Twin-stage Impinger Yes Yes No N/A
Andersen No Yes Yes Yes
Marple-Miller No Yes Yes No
Multi-stage Liquid No No Yes Yes
Impinger
Next Generation Impactor No Yes Yes Yes
1.6.7 General discussion
In general the more stages a testing device possesses the better the resolution of the 
results. Unfortunately this means that the device will require lengthy analysis. As 
discovered by Stein and Olson (1997) the ACI although an excellent device is subject 
to large inter device variability, the calculations governing impaction are precise so if 
the jets in the device are not particularly well defined then the impactor will have 
varied cut points. It would therefore be advisable to calibrate any aerosol testing 
instrument before use in the lab.
As the MSLI contains fewer stages but still provides aerosol fractionation of the 
diameters of interest then it may be better to use the device for more routine work 
such as quality control procedures (Holzner and Muller, 1995).
Single stage impactors or impingers are useful tools for screening and initial 
development as they are quick, efficient and accurate once calibrated. Even though 
these devices are included in the BP more evidence of an aerosol performance is 
generally required for regulatory purposes.
1.7 In vivo Aerosol Testing Methods
1.7.1 Pharmacokinetic studies
The method can provide a useful comparison of bioavailability between formulations 
and devices (Chrystyn, 2000) but gives no information on lung deposition patterns in 
the subject’s lung. Using the charcoal block method will stop any gastrointestinal 
absorption of the drug and so it can be said drug levels detected in the blood or urine 
are a results of pulmonary delivery of the drug. As drug delivery to the lung requires 
very small doses for clinical effects the method of testing blood and urine levels must 
be extremely sensitive and accurate. The pharmacology of many drugs means 
comparisons between them may be difficult as rates of absorption receptor binding 
time and drug metabolism can be markedly different (Snell and Ganderton, 1999).
1.7.2 Lung Casts
Cadaver casts have been made and investigated extensively for respiratory tract 
dimensions and geometry (Yeh and Schum, 1980) providing similar data to the 
Weibel model. The technique allows far more detailed lobar investigation and 
production of airway replicas up to generation 8 (Cheng et al, 1997). Airway casts 
may be used to assess deposition of radiolabelled aerosol or undergo calibration tests 
(Zhou and Cheng, 2000) as with other in vitro testing methods.
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Advances in microscopy techniques have allowed greater detail of lung surface 
structures to be analysed (Weibe and Laurensen, 1995 and Poinar et a l, 1996). These 
advanced techniques have focussed on respiratory healthy human subjects or animal 
models. To compliment the work into realistic models for aerosol testing it would be 
of interest to investigate the extent of obstruction to treatment in the lung and how this 
affects patients in specific disease states. It is unlikely that the methods outlined here 
could be used routinely for pharmaceutical aerosol assessment.
1.7.3 Planar (Two-dimensional) Imaging
Using radiolabelled aerosols allows the imaging of the drug in vivo. The technique is 
non invasive and observations can be made, as the drug is in situ. It is possible to 
incorporate the radiolabel molecule into the drag structure but this is rare. Therefore, 
a label may be associated with the drag molecule or simply added to the formulation 
(Zainudin et al, 1989) in both cases it is essential that the process can be validated 
and it can be seen that the radiolabel is acting as a good marker for the drag (Snell and 
Ganderton, 1999). Validation of the association of the label with the drag and the 
unchanged properties of die aerosol cloud can be carried out using simple imaging 
using controls and in vitro analysis with Andersen cascade impactors (Biddiscombe et 
al, 1993) or MSLIs (Steed et al, 1995).
A commonly used radiolabeling technique for salbutamol (Biddiscombe et al, 1993)
OOminvolved putting dry technetium pertecnetate ( TcCV) in a vial with the required 
surfactant, propellant and micronised salbutamol. The mixture was then placed into a 
sonic bath for thorough mixing and then sealed into a canister. It was demonstrated 
that the radiolabel was adsorbed onto the salbutamol by allowing the drag to cream
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out of suspension and then using simple imaging (with a control) checking the 
position of radioactivity emission. Substituting the drug for radiolabelled inert 
particles (e.g. Teflon) of a suitable size has also been used for such studies.
It has been shown that as well as labelling the drug the lactose carrier particles in a 
dry powder inhaler may also be radiolabelled (Karhu et al, 2000). Only a small 
amount of the inhaled lactose deposits in the lung. Most lactose deposition takes 
place in the mouth as design suggests and is swallowed.
Once the radiolabelled drug is administered to the subject the process of imaging can 
begin. The raw data gathered (primary counts) must be corrected for background 
radioactivity, radioactive decay and the depth of the signal in the body. Once these 
are corrected for the data are termed ‘secondary counts’. As the rays pass through the 
body they may become scattered or absorbed by the tissues of the body. Corrections 
for this type of loss of signal are termed ‘attenuation correction factors’ (ACF) 
(Pitcairn and Newman, 1997). They are ratios and are essential to avoid deposition 
underestimation. They take into account the density and type of tissues that the signal 
must pass through in particular the lung stomach and oropharynx (Snell and 
Ganderton, 1999), which obstruct the signal.
Planar imaging is an important technique aiding the understanding of drug deposition 
in the lung. Gamma scintigraphy studies allow imaging of a human lung after 
deposition of a radiolabelled aerosol has occurred. Gamma scintigraphy of course 
only detects and identifies the presence of the drug in the lung it does not indicate 
clinical effect (Newman, 1995). The oropharyngeal and respiratory tract may be
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investigated (Steed et al., 1995) and the lung system as a whole may be divided into 
discrete regions (Figure 1.4) of interest (Newman et al, 1998).
Figure 1.4. Schematic diagram of the ‘regions of interest’ as applied to planar 
imaging. (Adapted from Newman et al, 1998).
x
C = Central region 
I = Intermediate region 
P = Peripheral region
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The regions may be analysed individually and the ratios between them assessed. This 
can be particularly useful for making comparisons between devices and formulations 
(see below).
The technique is two-dimensional so although the central region contains mostly 
conducting generations they will overlap with some alveolar airways (Snell and 
Ganderton, 1999) as the structure of the lung develops also in the *z* direction. For 
each type of device planar imaging gives potential local bioavailability data (Newman 
and Wilding, 1998). It is therefore convenient to use the ‘regions of interest’ to 
compare between devices as outlined above.
Two-dimensional imaging has been used for the study of MDIs containing both CFC 
and HFA propellants (Richards et al, 1998 and Laube et al, 1998). The use of MDIs 
with spacer devices has also been attempted (Thorsson et al, 1998) where 
appropriate. The devices can then be assessed in vivo and comparisons drawn 
between use of MDI and MDI with spacer. Of more use to clinicians maybe are 
studies involving asthmatic patients (Borgstrom et al, 2000) even though this type of 
study makes experimental procedures more difficult to design. Patient usage 
variability when using a DPI (Turbuhaler™) was equivalent to that seen in healthy 
subjects. Variability when using MDIs was far greater highlighting the potential 
coordination and formulation problems that can be encountered. A comparison of 
solution and suspension MDIs in healthy and asthmatic subjects (Sanders et al, 1997) 
has found lung doses of the solution MDI to be almost identical between the two 
subject groups (healthy 61.13% ±10.95 n = 11, asthmatics 58.59% ±17.75 n = 9).
The total lung dose between the two groups when using a suspension MDI was found
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to be significantly different (healthy 17.42% ±5.32 n = 11, asthmatics 9.92% ±4.41 n 
= 9).
The technique is now well established for all types of inhalation method and has been 
used to assess novel pharmaceutical aerosol generators (Farr et al, 2000). The 
imaging process illustrates drug deposition in the lung which as has been discussed is 
more relevant than in vitro data. It has highlighted the overestimation of some 
(impinger) in vitro analyses giving a lower result for the <5pm (termed ‘respirable’) 
fraction in vivo (Newman, 1998).
It is important to be able to relate these studies to clinical responses; investigated by 
Smalldone (1996) and Laube (1996). Using both pharmacokinetic and gamma 
scintigraphy can yield different results (Borgstrom et al., 1998 and Pauwels et al, 
1997), as all deposition in the lung would be observed even though some of it will be 
removed by mucocilliary clearance before absorption into the bloodstream. It is also 
important to take into account radioactive decay and drug clearance (Bondesson et al, 
2000). Pauwles and co workers (1997) found that due to intra-patient lung function 
variability the relationship between pharmacokinetic and gamma scintigraphy must be 
subject to a specified regimen for any useful data to be gained the technique must 
therefore be standardised (Newman, 2000).
1.7.4 Three-dimensional in vivo imaging
Single Photon Emission Computed Tomography (SPECT) is a technique utilising 
radiolabeling of aerosols and imaging them in three-dimensions. Using a combination
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of SPECT and x-ray computed Tomography (CT), Perring and co workers (1994) 
developed a mathematical transformation of the lung into a series of hemispheres. A 
more detailed description of this may be found in section 2.3. After inhalation of a 
radiolabelled aerosol by a subject the model provides a framework for radiolabelled 
image signals to be assessed and quantified. The aerosol may be prepared in the same 
way as for 2D analysis and attenuation factors still have to be taken into account.
The model was used to assess the radioactivity signal after " mTc labelled albumin 
microspheres (Fleming et al., 1995) were inhaled by a subject. The results could then 
be expressed as total activity per shell as a percentage of the total activity detected. 
The hemispherical ‘structure’ was further improved after Martonen et al., (1995) 
devised a 3D branching network so the data could be approximated to generation 
number. The interpretation of the data into 23 generations is felt to be a little 
ambitious considering the distance between each generation at generation 6 to 7 is just 
on the limit of the resolution of the SPECT technique (0.8cm, Perring et al., 1994) 
and therefore the lower generation are well below the level. Generation 6 was found 
to be 0.9cm in the Weibel model and the length of generation 9 in each of the five 
lobes of the lung was found to be less than 0.9cm by Yeh and Schum (1980). This 
poses the question of validating the generation interpreting transformation.
Using the three-dimensional imaging technique outlined above nebulisers (Fleming, 
Hashish et al., 1996 and Fleming, Halson et al., 1996) and MDIs (Summers et al, 
1996) have been analysed in this way.
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Two-dimensional imaging requires less radioactivity to be present in the subject than 
three-dimensional imaging. It is quicker and unlike three-dimensional imaging 
validated (Newman and Wilding, 1999). It has been suggested that Planar imaging 
fits in between in vitro analysis and clinical data (Newman et al, 2000). The 2D 
technique does indeed give a better idea of deposition in the lung but it is felt that 
more advanced in vitro models would be more suitable if they could be validated 
using gamma scintigraphy both 2D and 3D and clinical data.
Another method of 3D imaging was described by Dolovich et al., (2000). Positron 
Emission Tomography (PET) utilises labelling of an aerosol with a position emitting 
isotope (e.g. nC, 13N, lsO, 18F). The signal was recorded from the subject after 
inhalation of the labelled aerosol by a ring of radiation detectors. This has an 
advantage over SPECT in that where a gamma camera takes images whilst rotating 
around the subject (64 projections around 360° each taking 30 seconds, Fleming et al., 
1996), taking a much longer time that PET ( as short as three minutes). The length of 
time taken during SPECT means the researcher has to account for decay of 
radioactivity but clearance from the lung is not accounted for (mucocilliary clearance 
is approximately 0.2mm min'1 in the trachea) (Marriott, 1990). This puts many 
possibilities for errors into the method of SPECT.
PET offers better resolution (4 to 5 mm) than SPECT but it is necessary to derive the 
subjects physiology before special attribution of signals can begin which can be time 
consuming and is expensive. The results of PET imaging are therefore less 
‘universal’ than SPECT and can be difficult to interpret.
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1.7.5 Mathematical models
Mathematical models have been designed to correlate with in vitro devices (Martonen 
et al., 1992) and more extensively lung geometry models in particular the Weibel 
model (Kim et al., 1983 and Martonen, 1993). Deposition models have limited 
success because the geometries and flow parameters in the lung are extremely 
complex (Hofmann, 1996). Possible factors to incorporate into the design of such 
systems are hygroscopicity, particle coagulation and geometries of deformed or 
diseased airways (Gradon and Podgorski, 1996).
It has been demonstrated that some mathematical models including the ICRP 
(International Corporation for Radiological Protection) model differ significantly 
from regional deposition studies using radiolabelled drug (Finlay et al, 1998). The 
advance of technology means more complex computations can be achieved and 
techniques in modelling physiological systems are constantly improving.
A general improvement of these models would be to include mucocilliary 
determinations. Mucus is present in the human body down to terminal bronchioles. If 
the body perceives formulation components to be ‘toxic’ hypersecretion and coughing 
may occur (Marriott, 1990).
1.8 Factors affecting deposition in the lung
The physical properties of the aerosol particles: particle size ( d a e ) ,  density of the 
particle material and the force of gravity, can all contribute to the deposition patterns 
of the aerosol particles in question. The breathing characteristics of a patient;
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including inhalation and exhalation flow rates, tidal volume and the period of breath- 
holding pause, have a wide variability and determine the concentration of the drug 
which is deposited in the lung. Along with patient variability the presence and 
severity of disease in the lung will greatly affect the level of drug deposition.
Mechanisms of deposition for medical aerosols are thought to include (Hickey, 1992, 
Haefeli-Bleuer and Weibel, 1988)
1.8.1 Gravitational settling
The force of gravity acts on the fine particles. Under laminar flow conditions, they fall 
under the force of gravity, a distance equal to the terminal velocity multiplied by the 
time of travel. Assuming the particles were evenly distributed over the cross section 
of an airstream, it would be possible to calculate the probability of deposition in 
tubular airways and in spherical alveoli.
The force of gravity acts on fine particles. The particles fall through the air at a 
constant velocity.
pt = Pgd2/18 r| (1)
d = particle diameter
P = density
pt = terminal velocity
g = acceleration due to gravity
r| = viscosity of air (1.9 x 10 Nm's)
24
1.8.2 Deposition by diffusion
Deposition by diffusion increases as the particle size decreases. However the force of 
gravity acts on the particles, as their mass becomes less, the force with which they are 
pulled becomes less. The particle diameter at which both processes have a combined 
minimum value is approximately 0.5pm. Particles of this size have the least 
probability of respiratory deposition.
1.8.3 Impaction
When particles are inhaled they follow the air-stream, if the conducting bronchiole 
suddenly changes direction a drug particle may tend to continue in its original 
direction of flow, possibly impacting on an airway wall depending on its momentum. 
A particle in this way may deposit on the airway wall. The effective stopping distance 
hs at right angles to the direction of travel in a curved tube is:
h s = P t P s i n o / g  (2 )
hs = effective stopping distance 
p = velocity of the air-stream 
ct = angle of the approaching bend 
g = acceleration due to gravity
The probability of inertial deposition I, is proportional to die ratio of the stopping 
distance hs to the radius R of the airway, that is:
I oc h/R  oc pt sincr/ g R (3)
I = probability of inertial deposition
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R = airway radius






The relative humidity in the lung is believed to be over 99% therefore particles 
inhaled into the lung will almost certainly undergo hygroscopic growth, increasing 
their probability of impaction or gravitational settling.
Deposition by interception and electrostatic precipitation can be important 
mechanisms of deposition in other situations but are not thought to contribute 
significantly to the in vivo deposition of medical aerosols. They may however play a 
significant role during the in vitro analysis and processing of some pharmaceutical 
aerosol devices (Byron et al., 1997, Peart et al, 1998 and Eilbeck et al, 2000).
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1.9 Aims and objectives
The purpose of this work is to design and develop a novel aerosol testing device for 
analysing medicinal aerosols. The devices currently in use do not adequately 
demonstrate where deposition will occur in the human respiratory tract. Using the 
available methods gives accurate data on die size of the particles contained in an 
aerosol however they do not reflect how these particles will act within the lung 
environment.
The devices described in this chapter adequately analyse an aerosol cloud with respect 
to aerodynamic diameter. Mathematical models predict deposition; radiolabeling 
studies visually demonstrate particle deposition. This thesis aims to provide an in 
vitro testing device more closely resembling the lung in its particle collection 
characteristics. Current analytical testing methods are unable to be correlated reliably 
with either mathematical predictions or gamma scintigraphy studies. A requirement 
for such a device is apparent in the industry.
An analytical tool giving quick reliable data on deposition patterns would be of 
benefit to formulators, analysts and quality specialists working in the aerosol field.
The cost and analysis time for such a model would be far less than running in vivo 
pharmacological or gamma scintigraphy tests on human subjects. The following work 




A novel aerosol testing device was required for use by the pharmaceutical industry. As 
previously discussed the current Pharmacopoeial standards are not necessarily the only or 
best methods to sufficiently demonstrate the in vivo deposition of a pharmaceutical 
inhaler. Many of the available devices were not designed with the intention of using 
them for these purposes. The new device was outlined by the Next Generation Impactor 
Group set up in 1996 (Wright and Shrubb, 1998). This consortium consisted of 12 
companies working together to design a new impactor with input from selected experts in 
the field. To gain an understanding of why a new device was needed assessments of the 
available impactors, impingers and in vivo techniques were made. Production of aerosols 
was also investigated to understand the laws governing generation and deposition of the 
drug particle.
Pharmaceutical aerosols are sized in order to predict if they are capable of reaching and 
deposition in the intended area of the lung. An ideal aerosol will consist o f particles of 
exactly the same size, as discussed previously this is not the case. To discover the 
characteristics of a particular formulation it is necessary to perform sizing experiments. 
The preferred choice in industry at the moment is the Anderson Cascade Impactor (ACI) 
this gives a good range of discrete size fractions. The data produced may be manipulated 
to calculate the mass median aerodynamic diameter and the geometric standard deviation.
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This data was used to show how well your formulation performs and during quality 
control procedures.
2.2 Development of the Shell Model Lung
2.2.1 Purpose
When designing a novel device it was decided to look at the whole area of aerosol 
science with consideration to the issues above. It was thought that however precise, 
informative and practical the impactors currently in use are they tell the operator very 
little about how the aerosol will behave in the patient. The impactors we use give 
invaluable data required for the development, comparison and regulation of medicinal 
aerosols. Such aerosols cannot be tested in vivo for these purposes on a day-to-day basis.
The importance of y-camera imaging of radiolabelled drug has been discussed in 
Chapter 1. This technique produces data showing exactly where in the patient’s lungs the 
aerosol deposits. Using SPECT analysis in conjunction with pharmacokinetic studies 
produces a general profile of the activity of the drug in the patient. It would be extremely 
complicated to design a model to perform this function in vitro. It may be possible 
however, to combine aspects of the in vivo and in vitro studies to reflect the chance of the 
drug particles reaching the desired space in the patient’s lung and producing an effect.
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For the purpose of designing a useful analytical tool for laboratory use it was decided to 
base the design on the 3-dimensional studies of human lungs as described below and not 
the 2-dimensional situation as used by Newman et a l, (1998). The 3-dimensional aspect 
of an in vitro model would of course be closer to the in vivo situation.
If the in vivo dimensions of the human lung were included in the model it would be 
reasonable to assume the in vitro model would behave in a similar fashion. Keeping the 
model as simple as possible even though a compromise was crucial to its use as an 
analytical tool. The casting of human airways has been described in section 1.8.3. This 
work is important to our understanding of the effects of geometry on deposition profiles it 
would not be a good laboratory tool as it represents the situation of airway geometry of 
one deceased patient. The cast made were rigid and so do not accurately reflect the 
‘breathing’ motion seen in vivo.
SPECT (as discussed in section 1.8.5) analysis gives three-dimensional information on 
the deposition patterns of radiolabelled aerosols in the lung. To analyse the information 
obtained a mathematical hemispherical transformation of the lung (figure 2.1) was 
developed by Perring et al, (1994) and later used by Fleming et al, (1995).
2.2.2 Details of SPECT mathematical transformation
The lung being modelled is the right lung and not the whole lung system. The lung 
‘space’ was considered in relation to a three-dimensional matrix of cube volume elements
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or voxels. Its x, y, and z co-ordinates described each voxel. The centre of the lung (xc, yc, 
Zc) was defined as the point where the main bronchus crosses the surface boundary of the 
lung space.
Figure 2.1. Hemispherical Transformation (adapted from Perring et al., 1994)
Using data obtained from gamma scintigraphy studies and anatomical dimensions of a 
subject from an MRI study allowed the relation of aerosol deposition to physical 
anatomy. Mathematically modifying the subject’s lung into the hemispherical structure 
and ‘superimposing’ it onto the SPECT data allows 3-dimensional view of the spatial 
distribution pattern in the lung.
The analysis of the radionuclide distribution is limited by the resolution of the SPECT 
imaging process, which is in the order of 1 cm. Therefore, due to the effective radius of 
the lung being approximately 10 cm, ten shell divisions were used.
Generation 1 .23 Shell 1 10
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The Shell Model Lung was based on these hemispherical transformations. It was hoped 
that combining the model for computational assessment of real patient data with an 
internal structure representative of the in vivo situation a compromise between in vitro 
and in vivo aerosol testing could be reached. The model was designed as a shell 
structure. In order for the flow of air and particle separation to occur the shells had to 
contain holes. It was decided to try to replicate the dimensions of the human airways for 
the three-dimensional space that the shell occupied. This data collection is described 
below.
2.2.3 Details of the Weibel model of the airway tree
The model was based on data o f airway dimensions from the Weibel model o f the airway tree 
(Weibel and Gomez, 1962). The Weibel model o f the airway tree is shown below for generations 
0 to 14, data for the model was collected after many measurements taken during post mortem 
studies.
Figure 2.2. Typical path airway model of a human lung:
Generation Number Airway Segment Length (cm) Total airway cross 
_____________ N(z) Diameter (mm)______________ Section (cm2)
0 1 18 12 2.54
1 2 12.2 4.76 2.33
2 4 8.3 1.9 2.13
3 8 5.6 0.76 2
4 16 4.5 1.27 2.48
5 32 3.5 1.07 3.11
6 64 2.8 0.9 3.96
7 128 2.3 0.76 5.1
8 256 1.86 0.64 6.95
9 512 1.54 0.54 9.56
10 1024 1.3 0.46 13.4
11 2048 1.09 0.39 19.6
12 4096 0.95 0.33 28.8
13 8192 0.82 0.27 44.5
14 16384 0.74 0.16 69.4
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Several assumptions were made:
1. The conducting airways (up to generation 14) were considered to consist of airway 
paths each of which branches outwards from the centre of the lung and around a 
radial path, terminating in a acinus
2. The acini fill the remaining volume uniformly
In this model there are equal numbers of airway paths in each of the generations 1 to 14, 
the Weibel model contains progressively fewer actual airways in the lower generations.
In the hemispherical model the airway paths can be considered to be merging together to 
produce the smaller number of actual airways, each of which has a progressively larger 
cross-sectional area.
The path length distribution includes all the statistical extremes of variation in the Weibel 
model. The airways are described as a branching ‘tree’, which is divided into 
generations, the trachea being generation 0 and the alveoli generation 23. Many of the 
airways do not branch from generation 1 through to 23, as alveoli are present on the 
airways representing lower generations i.e. close to the bronchus. Generations 1 to 14 are 
considered to be the conducting airways and generations 15 to 23 the acinar airways. 
Acinar airways are the complex of alveolated airways connected to a first order 
respiratory bronchiole. The model is suggesting that the ‘conducting’ airways are 
divided into ten sets each of which ends in its given shell. The model described here does 
not take into account the sharp or subtle bending seen in the airways resulting in longer
33
path lengths and higher surface areas. To make the design and manufacturing processes 
of the SML easier and quicker, the model does not represent any irregularities in 
branching of the airways the model was designed to a symmetrical theory.
2.2.4 Transformation
To develop the Shell Model Lung, Weibel data for generation 1 to 14 was transformed 
into data representing 10 shells of the three-dimensional shell model.
As the model is based on the hemispherical transformation model it was decided to 
acknowledge the constraints placed on that model when designing the SML. The centre 
of the lung in relation to the Weibel model was taken to be around one third along the 
length of the main bronchus, generation 1. It was therefore necessary to begin the 
iterative transformations of the Weibel data with generation 1 even though this generation 
does not appear in the shell structure. This would enable a better fit when trying to 
interpret the results from the SML in relation to SPECT data. Figures 2.3 and 2.4 show 
the graphs drawn to complete the data transformation. The iterative transformation was 
therefore, began at generation 1.4 to represent shell 1 increasing in increments o f 1.4 until 
10 shells were accounted for.
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The values for the airway segment diameters at the point o f  each shell were read directly 
from the graph see figure 2.2
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To fit total airway cross-section diameter (single, 3 parameter exponential growth).
f=y0+a*exp(b*x) (4)
Sigma Plot (4.0) description o f  the equation:







R = 0.99986460 Rsqr = 0.99972922 Adj Rsqr = 0.99967507 
Standard Error o f  Estimate =  36.6890
Coefficient Std. Error t P
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yO 198.4697 17.7048 11.2099 <0.0001
a 12.5974 0.9598 13.1255 <0.0001
b 0.4484 0.0055 81.7249 <0.0001
x  generation
Analysis of Variance:
DF SS MS F P
Regression 2 49697995.0167 24848997.5084 18460.2694 <0.0001
Residual 10 13460.7990 1346.0799
Total 12 49711455.8157 4142621.3180
Statistically equation 4 is satisfied and so it was used to calculate total airway cross 
section at each shell point.
2.2.5 Incorporating the transformation into the design
It was decided that the spacing of the holes over the shell surface should be equidistant. 
This makes the model symmetrical and makes the design and manufacture processes 
simpler.
Surface area o f  a hemisphere o f  radius r:
In t1 (5)
It is necessary to leave a small amount of surface area for the attachment of each shell to 
the back plate it was found that the area within a distance, 81, of 5mm from the shell edge 
was sufficient.
Surface area of space required for fitting:
51 * 27ir (6)
Therefore the length o f  the equivalent square:
(2m* - 81 * 2m  f 5 (7)
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Number of holes on one side of the equivalent square:
Vn  (8)
Equation for the distance between each hole (D):
D = ((2m2 - 81 * 27tr)/N)°5 (9)
2.2.6 Calculated dimensions
Using this equation, hole centre to hole centre distances were calculated. The number of 
holes in each of the 10 shells of the SML is given in figure 2.5
Figure 2.5 Calculated dimension for the SML
Shell Generation Airway Segment 
Diameter / mm




1 1.4 10.6 222 2.5
2 2.8 6.0 242 7
3 4.2 4.2 281 20
4 5.6 3.0 353 50
5 7.0 2.3 489 117
6 8.4 1.8 743 292
7 9.8 1.25 1218 993
8 11.2 1.0 2109 2686
9 12.6 0.9 3379 5940
10 14.0 0.7 6906 16059
It was decided for economical and analytical purposes to have only 5 shells in the model. 
The even numbers; 2,4,6,8,10 were chosen; this makes the model symmetrical and 
includes the final stage.
Each hole represents an airway in that particular three-dimensional space within the lung. 
The remaining volume was considered to be uniformly filled with acini even though the
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shells would act as the collecting surfaces for particles in the model. The holes were 
drilled into each shell at 90° angles to the surface to replicate the varying angles achieved 
by airway branching and to reduce burring of the metal. The actual dimensions of the 
constructed SML are given in Figure 2.6 and 2.7.
2.2.7 Actual dimensions





Thickness / mm 
(St Dev)
Mean Shell External 
Height / mm
Shell 1 35.5 3.13 (0.03) 22
Shell 2 77.5 2.0 (0.05) 44
Shell 3 110.6 2.88 (0.07) 62
Shell 4 160 3.04 (0.01) 83
Shell 5 200 2.97 (0.03) 102
Outlet Pipe 10.12
Figure 2.7. Hole Measurements for each shell (n = 9 in all cases)
Shell Mean Hole Diameter / mm 
(St Dev)
Number of Holes (N)
Shell 1 5.43 (0.09) 7
Shell 2 3.02 (0.08) 43
Shell 3 1.82 (0.03) 298
Shell 4 0.99 (0.01) 2478
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2.2.8 Material consideration
The structure of the model was required to be rigid and rugged enough for everyday use. 
Glass would have been too difficult to manufacture with the necessary holes in each 
shell. It would have been heavy and rather delicate. Another option was to form the 
structure in silicone this seemed too costly and time consuming after investigation.
Aluminium was chosen as the material for the SML, it is a cheap, light inert metal. The 
University of Bath Science Workshop had considerable experience of working with 
aluminium so the manufacturing process could begin as soon as the design was 
completed.
2.2.9 Problems encountered with manufacturing
Each shell had to be cut from a solid block of aluminium to create the hemispherical 
structure. Several production methods were investigated before this was chosen such as 
spinning or forming a mesh to create the shell structure. It was a costly and time 
consuming method but, proved to be the only one that could be carried out successfully 
on the premises and within the time constraints. Unfortunately the Workshop could 
manufacture only shells 1,2 and 3. Shells 4 and 5 were too big to be milled in the same 
way. The machinery used at the Workshop was too small to manufacture the larger 
shells.
Until a manufacturer could be found to make the larger shells it was decided to press on 
with characterising the incomplete SML. A large cylinder was fitted over the shells to
40
create a final stage including an outlet pipe for a vacuum pump to be attached. The initial 
SML design is shown in Figure 2.8.
The initial data collection using the incomplete SML is presented in Chapter 5.





To complete the SML it was necessary to review the initial design configuration. 
Considering shell 5 and the large number of holes necessary in the shell, it was decided
this shell would be the final collecting stage. This resulted in the cylinder being 
discarded and the model becoming more compact. The hole content in shell 5 as 
designed would make it very time consuming and more importantly extremely expensive 
to manufacture.
The redesigned shell 5 contained no holes apart from an outlet pipe leading to the pump. 
The cost of the model was reduced by redesigning shell 5. The complete revised Shell 
Model Lung is shown in as a drawing in figure 2.12 and a photograph in figure 2.13. It 
took a few months to find an engineering company willing and able to undertake the 
manufacture of the final shells. Fortunately a company in Bath was found (Sayers 
Engineering) who had sufficiently large and advanced machinery to complete the job.
The manufacturing process of the larger shells took some time to complete, as they 
required more precision during manufacture than the smaller shells.
2.2.10 Bifurcation re-manufacture
The bifurcation entry port of the SML was manufactured to 20mm to allow the USP 
throat to be fitted directly to the SML. To represent the bronchiole, the original design of 
the bifurcation entry port had an internal diameter that decreased to 12mm (see figure 
2.9). It is understood that the narrowing of the bifurcation entry port would have 
increased the flow velocity as the fluid moves through this area. Furthermore, the surface 
of the original bifurcation entry port was very rough and quite crude; this would have the 
effect of introducing turbulence into the flow as it passes this area. After some initial
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measurements, it was decided to have the part remade in a more appropriate three- 
dimensional aspect to the specified dimensions. Sayers Engineering o f  Bath made the 
new bifurcation (figure 2.10).
Figure 2.9 Photograph o f  the old Bifurcation.
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Figure 2.10 Photograph of the new Bifurcation.
A series o f  experiments to show the improved three-dimensional SML are detailed in 
chapter 5. All calibration work was performed using the new bifurcation. Experimental 
work was carried out to show that the new bifurcation improved collection in the shells o f  
the SML (section 5.11).
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2.2.11 Theoretical cut point calculation for the SML bifurcation
It was first essential to calculate the theoretical Reynolds number at the bifurcation 
(Marple a/., 1974):
Re = Reynolds Number 
p = 1.205 kg m'3
V = Velocity at the bifurcation (ms'1) 
W = Diameter of bifurcation (m) 
p =  1.822 x lO '5 P as 
At a flow rate of 301 min'1:





A = 7cr2 (12)
Where,
r = 0.005m
A = 7.854 x 10'5 m3 (13)
Therefore:
V = 5 x IQ-4 
7.854 x lO '5 (14)
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V = 6.37 m s"1 (15)
Calculating the Reynolds number using (10):
Re = 1.205x6.37x0.01
1.822 x lO '5 (16)
Re = 4213 (17)
In consideration of the cut point at shell 1 it was necessary to assume veiy simplistic 
boundary conditions:
1. The velocity and flow field were in the direction of the bulk flow only
2. Velocity was zero at a solid surface
2.2.12 Geometric considerations
It was shown by Huang and Tsai (2001) that gravity considerations should be taken into 
account for accurate cut point calculations. It was shown that if Re were less than 1500 
the gravitational force would reduce the Stokes number and thus affect the cut point 
diameter. At a Re of over 4000 as calculated in equation (17) it is reasonable to assume 
in theory no gravitational effect on the calculated cut point. As airflow exits the 
bifurcation it was assumed that the ‘jet’ was round.
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2.2.13 dso Calculation
In the simplest case for a circular ‘jet’ exit it can be said when designing a regular in-line 
impactor that the square root of the Stokes Number (Stso172) may be assumed to be 0.5 
(John, 1999). However the calculation depends on the impactor being vertical and the 
impaction plate being horizontal to the direction.
Using an assumed stokes number as suggested by Hinds (Hinds, 1999) of 0.49 in 
calculating the cutpoint of an impactor with a circular nozzle then:
C~ "1 ^
d5o (Co05) =-{ 9 ft n Dj3 Sty, I
L  4ppQ J  (18)





Figure 2.11 Table of calculated cutpoints at specific flow rates the values calculated from 
equation 16 for the d50 cutoff diameters at 20, 30 and 601/min assuming a 10mm 
bifurcation diameter.





It is of course possible using these types of calculation to design an impactor giving 
desired cutpoints (Marple and Willeke, 1976). Using these calculations as an estimate of 
the cutpoint size and the recommendations for ensuring such an impactor gives the 
sharpest cutpoints it would be possible to devise specific instruments for the analysis of 
aerosols.
2.2.14 D50 calculation using measured dimensions
The actual diameter of the bifurcation at the exit was found to be 12mm. Performing the 
calculation again using this measurement gives:
Where, r = 0.006m
A =  1.13 x 10-4 m3 (20)
Therefore:
V = 6 x IQ-4 
1.13 x lO -4 (21)
V = 5.31 m s '1 (22)
Calculating the Reynolds number using (10):
Re =1.205x5.31 x0.01
1.822x 10»-5 (23)
Re = 3511 (24)
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Using equation 17 above:
dso CICc = 10.3 x 10'6 m (25)
Correcting for Cunningham slip correlation, equation (18) gives:
d50 = 10.3 -  0.078 = 10.22 pm (26)
It is possible that the geometrical constraints on the model and gravitational effects on the 
particles (Re < 4000 in practice see equation (24)) reduce the cut point. Calculating the 
cut point using equation (17) (disregarding the Reynolds Number) gives an agreeable 
value. Due to the geometry and direction of flow it is difficult to accurately predict the 
Reynolds number at the many positions therefore an approximation has been made (a 
Computational Fluid Dynamics model in figure 3.6 shows that the pressure in shell 1 is 
uneven and figure 3.20 demonstrates that the area is subject to turbulence).
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2.2.15 Line diagrams



















Figure 2.14 Photograph of Shells 1, 2, 3 and 4
Figure 2.15 photograph o f Shells 1,2,3 and 4 (interior)
Chapter 3 Design and analysis of the 2-dimensional 
Shell Model Lung (2DSML)
3.1 Introduction
The 2DSML was devised to compare the CFD results with a physical model. If the 3D 
model was to be assessed for its fluid flow properties it would have been very complex to 
incorporate the necessary features into the model. It is necessary to sample the airflow in 
the cavities of the shells and throughout the model as a whole. This would mean extra 
holes would have had to be put into the model to allow this to happen. These extra holes 
would have to be blocked up when the model was in operation as an aerosol testing 
device. The difficulty arises due to the hemispherical structure of the design it would be 
rather difficult and costly to produce these extra sampling points in the model and very 
awkward to reassemble the model once the sampling line was inserted in the correct 
position. As the model is made of aluminium it would then be impossible to see if  the 
sampling line remained correctly positioned after reassembly.
3.2 Design of the 2DSML
The potential solution to the problem was to design a 2-dimensional model. It would be 
quite impossible to manufacture a truly 2-dimensional physical model so a thickness of 
around 20mm in order for the required number of holes to be drilled into each shell was 
deemed to be satisfactory for the design brief and manufacturing requirements. The aim 
was to build a model incorporating as many of the three-dimensional models features as 
possible.
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The model was turned from a complete plate of aluminium and then the parts were 
separated once the basic design structure had been formed. The work took a little time to 
complete but the two-dimensional model was far less costly than the three-dimensional 
model.
Each two-dimensional shell was designed as previously discussed in section 2.3 and 
figure 2.7 shows the line diagram used. The two-dimensional shells were designed as 
outline in figure 3.1 below.
Figure 3.1. Table of design shell dimensional data. Each shell to have fixed 3rd 











To conserve the features of the three-dimensional model as much as possible the number 
of holes in each two-dimensional shell was based on the % hole content of each three- 
dimensional shell. Using data for the three-dimensional model the % Hole in each shell 
was calculated, figure 3.2 contains the data for these calculations.
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Figure 3.2. Data from the 3DSML to calculate the % Hole in each shell.
Shell Hole Diameter Surface Area Number Surface Area % Hole 
mm of Hole of of 3D shell in
mm2 Holes mm2 shell
1 5.43 23.2 7 2513.3 6.5
2 3.02 7.2 43 10053.1 3.0
3 1.82 2.6 298 22619.5 3.4
4 0.99 0.7 2478 40212.4 4.7
The % Hole contained in each shell was then transformed into a number for hole content 
in the 2DSML. Figure 3.3 contains the data for these calculations.
Figure 3.3. Calculated data for the number of holes in each shell calculated from the % 
hole in each shell of the three-dimensional model. ‘Number of holes’ was rounded to the 
closest whole number.
Shell Hole Surface Area Surface Area % Hole Number
Diameter of Hole of 2D shell in of
Mm mm2 mm2 shell Holes
1 6 28.3 1256.6 6.5 3
2 3 7.1 2513.3 3.0 11
3 1.8 2.5 3769.9 3.4 51
4 1 0.7 5026.5 4.7 304
Unfortunately the holes could not be manufactured to the exact specified diameters as 
stated however the actual diameters were a close alternative, figure 3.4 gives the data for 
the actual manufactured dimensions of the 2DSML.
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3.3 Manufacture of the 2DSML








of 2D shell 
mm2
% Hole Number 
in of 
shell Holes
1 5.74 25.8 1256.6 8.2 4
2 3.28 8.4 2513.3 3.3 10
3 1.74 2.4 3769.9 3.2 51
4 1.02 0.8 5026.5 4.9 310
As the hole diameter in Shell 1 was less than the 6mm designed diameter it was decided 
to have 4 holes in the shell instead giving a ‘% Hole in shell’ value of 8.2%. Even 
though this seems a high value it was in fact closer to the original design specifications 
for the three-dimensional model as outlined in Section 2.3.3. Again with the second shell 
as the hole diameter was more than the specified value it was decided to round down the 
number of holes to 10 giving a ‘% Hole in shell’ value of 3.3%.
Unfortunately a mistake was made in the two-dimensional Shell 4 and 310 holes were 
drilled instead of 304, the calculated distance between each holes was slightly wrong and 
the computer equipment drilled according to the programmed data. This gave a ‘% Hole 
in shell’ value of 4.9% this was deemed satisfactory (+0.2%). It would have been too 
expensive to re-make the one shell as the whole model was formed from one piece of 
aluminium.
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Once the drilling of the holes was completed the model could be mounted. Perspex was 
chosen as the material for enclosing the model. It was necessary to make a tight seal 
between the model and the case and the case had to be transparent. To make the 
measurement necessary it was also essential that the material could be worked with 
easily. For this reason glass was not chosen as Perspex is more pliable and lighter. The 
completed model is shown as a photograph in figure 3.5. The Perspex plates were bolted 
together to form a reliable seal. As it was not intended for the 2DSML to be used as an 
aerosol testing device the use of Perspex and the electrostatic considerations of this type 
of material on particles was irrelevant.
The design, manufacture and analysis of the 2DSML were personally directed at all 
times. The experimental work described below was carried out in the department of 
mechanical engineering at the University of Bath and was at all times personally 
supervised.
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Figure 3.5. Photograph of the 2DSML
3.4. Computational Fluid Dynamics
Dr Ming Li at the Department o f Mechanical Engineering, University o f Bath, 
constructed a CFD model o f  the 2DSML. Data for the design were provided and the 
project directed in conjunction with the design and manufacture o f  the 2DSML. The 
software used was STAR-CD (Version 3 Computational Dynamics, London, UK) a finite 
volume based package. A brief summary o f the qualities o f  CFD will be given followed 
by a summary o f the work carried out on this particular project.
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3.4.1 Basic Principles
The modelling of fluid flow begins by ensuring the conservation laws of physics are 
applied. These are:
1. Mass is conserved
2. Rate of change of momentum = sum of forces on a fluid particle (Newton’s 2nd 
law)
3. Rate of change of energy = sum of the rate of heat addition to and the rate of work 
done on a fluid particle (1st law of thermodynamics)
The fluid can be attributed velocity, pressure, density and temperature if  these conditions 
are adhered to and the operator has set conditions appropriately. The fluid is considered 
to consist of fluid ‘particles’ the smallest amounts of fluid able to be reliably modelled
i.e. individual molecules have no effect on the qualities being investigated.
The conservation of mass in the fluid essentially requires the increase of mass within the 
fluid element to equal any net input of mass into said element. This ensures that an 
increase in pressure cannot happen unless the operator allows fluid to enter the system at 
a specified direction, order and dimension.
The rate of change of momentum may be considered to be an outcome of the allowed 
forces acting on the fluid particle as programmed into the system by the operator. The 
forces acting on the fluid particle can be surface or body force:
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Surface forces: Pressure forces
Viscous forces




It is obviously vital that the operator enters such force parameters so the system can begin 
to function as would be expected under physical experimentation.
The derivation of the energy equation from the 1st law of thermodynamics ensures that 
heat energy is accounted for when assessing the total energy of a fluid particle. Heat 
energy must be allowed to flow through the system for accurate modelling (Versteeg and 
Malalasekera, 1995).
The model that was constructed was made as simply as possible allowing faster 
computations. Modelling consists of building a mesh of the design and incorporating as 
much detail as allowed into the design. Once the boundary limits and interior framework 
are set the operator may begin setting the fluid flow conditions. The advantage of using 
this technique is that the model design once created may be relatively easily changed.
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This is of great use when carrying out a project such as this where physical modelling 
was found to be very costly and time consuming.
It was decided that the whole model should be analysed using CFD but constructed in 
two-dimensions only. The first CFD model was based on the incomplete SML and those 
are the diagrams that will be investigated. If more time could have been allowed then the 
model would have been investigated further and related to work presented further in this 
chapter.
It is possible using this technique to model the velocity of the fluid flow. This is 
extremely useful when looking at areas that potentially cause turbulence in a model. The 
pressure changes in the system can be assessed as can be seen in Figure 3.6 below. 
Particle deposition or particle tracking can also be analysed with CFD.
The results from the model in figure 3.6 indicate that there are significant pressure drops 
as the fluid moves from the bifurcation through to shells 1, 2 and 3. This would suggest 




Figure 3.6. CFD diagram o f pressure changes in the 2DSML. The inlet velocity was set 
at 1.28ms'1.
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3.4.3 Results and Discussion
CFD has many limitations but it is a very useful tool when investigating design and 
implementing changes to those designs. The technique cannot be used alone without 
physical experimental measurements taking place but with careful validation procedures 
it may be possible to use the tool more routinely. It is essential that the system operator 
understands fully the CFD software and its limitations and the design to be analysed.
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3.4.4 Current relevant CFD uses
Many stages of the lung and simplified impactor stage geometries have been studied 
using CFD. Airstream effects in parts of the lung and canine whole lung systems have 
been investigated.
Li and Edwards, 1997 have made throat geometry assessments. They used simplified 
(USP) throat geometries comprising a 90° bend and a more anatomically correct throat 
model. Both geometries were considered in three-dimensions. Particle deposition was 
estimated by making the internal surfaces of the model ‘wet’, this instruction is possible 
when using the technique.
It was seen that the anatomic throat more closely resembled an empirical formula 
developed earlier, which was based on in vivo comparisons. The reliability of this 
method was not sufficiently evaluated in the text of the reference. However, over 80% 
deposition was seen of 10pm particle in the throat and approximately 40% deposition of 
lpm  particles was seen thus, it is reasonable to accept the comparative study in the 
interest of throat deposition only. A USP throat was used as the inlet port to the SML 
and the 2DSML in a two-dimensional capacity.
The wide variation of predicted deposition between three-dimensional and two- 
dimensional models reported should be expected as any surface roughness or changes and 
variation of geometry will introduce turbulence and thus affect deposition. It was clear 
the particle deposition seen for the studied simplified (USP) throat was less than in a
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more ‘correct’ anatomical throat, 10pm at approximately 10% and 1pm particle 
deposition at around 10% also.
As a DPI was used as the model aerosol in this study it was necessary to ascertain the 
deaggregation forces acting on the drug and carrier particles. If particle were in a more 
turbulent environment the direction and thus velocity of such forces will be less 
predictable and deposition possibly enhanced.
When investigating the effects of lung geometry on airflow it is necessary to look at 
small changes throughout the lung. The easiest points of interest to look at are probably 
bifurcation regions. It is relatively easy to set up CFD models of bifurcating tubes of set 
diameters and branches at realistic angles. Carinal ridges at the point of bifurcation will 
have effects and influences on the airflow through the region. Martonen et al, (1994) 
looked at the effects of carinal ridges in generations 6 to 7 of the Weibel model. For each 
ridge shape, parabolic, blunt, saddled and asymmetric at high flow rates (qualified at 
601 min'1) a higher incidence of turbulence was found than seen at sedentary (7 1 min'1) 
and light activity (20 1 min’1) breathing patterns.
Ignoring the effects of the carinal ridge it was seen that plug flows in the parent branch 
result in less skewed daughter branch flow profiles than when the parent branch displays 
parabolic of fully developed flow. In the investigations made on the 2DSML it was 
assumed that the flow was fully developed throughout.
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Geometry features as presented here will affect turbulence, airflow and aerosol 
deposition. The assessment made was simplified but indicates further and more detailed 
examples must be investigated.
A physiologically realistic bifurcation model has been characterised by Balashazy et al, 
1996. Based on the Weibel lung model at generations 3 and 4 (56mm □ 45mm at an 
angle of 35°) the model assumes the airways are smooth and round.
The airflow was seen to become turbulent after entry into the daughter branches at the 
boundary opposite airflow entry. The amount of turbulence in reality is likely to be much 
higher as geometry features are present in the airways. Boundary conditions are 
extremely simplistic and symmetrical.
The ‘realistic’ bifurcation does not model the airflow and deposition sufficiently. It is 
however a good basis for improving CFD models and introduces the ideas of actual 
geometry and the proposed effects on CFD models.
A double branching bifurcation model has been used to assess the deposition and 
dispersion of an aerosol bolus (Lee et al, 2000). The model although improving on the 
techniques employed by Balashazy et al, was till found lacking but proved far better 
agreement with physiological models described. Increased complexity has obviously 
become possible as technology advances; the techniques of investigating bifurcational 
disturbances in airflow require further refinement.
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The SML and 2DSML contain only one bifurcation representing the transition between 
the larynx and bronchi. The bifurcations as presented above refer to generations deeper 
in the lung. It is likely that the SML as an over-simplification of the situation will collect 
particles in this region of higher MMAD than would be the case in reality. Anatomically 
correct models would include the geometries that make turbulence a feature of the 
airflow in the respiratory tract and allow smaller particles to deposit.
A significant improvement in the modelling of the lung was made when a realistic CFD 
model of the canine bronchial tree was constructed from a cast having undergone 
tomographic scans (Perzl et al, 1996). The data gained from this method were of very 
high quality but limitations of the technology resulted in the geometry data having to be 
reduced so the computation could be performed within reasonable time restrictions. The 
model was of course very realistic and the authors propose it may be used for studying 
particle deposition.
Any simulations carried out would have to be verified by experimental means. Animal 
studies are essential for many drug evaluations but when concerned with particle 
deposition in the human respiratory tract airway geometries the canine and human 
respiratory structures are different and this must be taken into consideration. If drug 
deposited in the lung is to have a local or systemic effect it is vital to understand where 
deposition will occur in a human subject as drug action depends on receptors, areas of 
smooth muscle or entry into alveolar regions must be targeted. It is unlikely that canine
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models will provide good correlation but the CFD model is of great use in understanding 
the complex geometries present.
It is clear from the literature that using numerical and CFD models to study the lung is 
valuable and becoming more realistic as technology improves. The importance of 
physiologically correct, three-dimensional models and the inclusion of realistic flow 
patterns were noted by Ferron and Edwards, (1996) for accurate CFD modelling.
Considering particle flow and deposition in the lung system requires taking into 
consideration the pitfalls present in CFD modelling techniques and applying further 
appropriate theoretical situations. The behaviour of a commercial aerosol in the lung 
system put further constraints of shape, hygroscopic growth, coagulation of particles and 
mass changes as particle deposition takes place in the system.
The constant variation of lung morphology as breathing occurs and the transition from 
conducting airways to regions where gaseous exchange takes place pose further questions 
and challenges for the mathematical and computational modellers.
Particle deposition even when considering situations will not be realistic if  the airways 
modelled are smooth straight tubes as presented by Gradon and Podgorsky, (1996). It is 
of vital importance that oversimplification does not greatly affect the accuracy of the 
results (Finlay et al, 1996). It was demonstrated (Zhang et a l, 1996) that even in simple 
bifurcations flow patterns were complicated. It is drawn to the attention that the working
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relationship between operator, model and software must be very good and never reduce 
the merits of each factor. If a CFD solution is physically investigates and qualified then 
it can be held as valid.
The most advanced CFD model of the respiratory tract to date has been designed and 
developed to generation 4 (Clayborough et al., 2001). The model clearly shows the 
degree of asymmetry present in the lung system. It was demonstrated, using a laminar 
flow, due to the constriction of the airways around generation 4 air velocity increases. It 
is expected that after this area the flow velocity will fall as the number and surface area 
of the airways increase. The authors hope to develop the model further and use the 
technology to incorporate aerosol devices into the system but due to the complex nature 
of the project it is expected to take quite some time.
3.5 Analytical Model
3.5.1 Introduction
An analytical model was designed by Daniel Clark, a final year MEng. student at the 
University of Bath to predict airflow characteristics at specified points through the 
2DSML. This model was designed and constructed under personal direction as an 
alternative to using CFD it was a quick easy to understand and modify technique that 
requires no computer work. The model can be modified when experimental 
determinations provide evidence to give a more realistic representation of the physical 
model. The modelled factors were:
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•  Reynolds number (Re)
• Flow regime (either laminar or turbulent)
• Velocity (v/ms"1)
• Loss in total pressure, relative to atmospheric conditions (APo/Nm'2)
•  Loss in static pressure, relative to atmospheric conditions (A P/N m ')
•  Total pressure (Po/Nm'2)
•  Static pressure (P/Nm'2)
Figure 3.7 contains a line drawing o f  the positions o f  the points (stations) in the 2DSML. 
The model is arranged on a spreadsheet and the user simply types in the relevant 
conditions: flow rate and atmospheric temperature and pressure (Clark, 2001)








To ensure the model is user friendly and quick to use several assumptions have been 
made.
1. Compressibility is insignificant and so is ignored. The estimated velocity at 
which compressibility effects become apparent was 100 ms'1. It was shown that 
the maximum velocity achieved in the 2DSML was less than 14 ms'1.
2. Air temperature was constant throughout the model.
3. Flow was steady; any fluctuations in pump performance were ignored.
4. Airflow velocity changes were considered to be instant.
5. Modelled airflow was considered to be one-dimensional.
6. Airflow was considered to be evenly distributed around each hole and shell.
7. Jet effects throughout the model were ignored.
8. Flow at the bifurcation region was assumed to follow in the direction of shells 
only.
9. All surfaces were considered to be ‘fluid dynamically smooth’.
The assumptions made are indeed simplistic but for the purposes of the work in the time 
frame allowed it proposed a suitable mathematical model of the 2DSML. In particular it 
is unlikely that there will be insignificant jet effects and they will be most apparent in the 
lower regions of the shells, as the position of the pump will probably influence the 
direction of flow. This o f course leads to an uneven distribution of flow through each 
hole and subsequently each shell.
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The analytical model was used to compare experimental data collected using the 2DSML; 
an account of this work will be given below.
3.6 Pressure Testing
3.6.1 Introduction
The purpose of constructing the analytical model was to relate it to physical experimental 
data collection in the 2DSML and assess its suitability. It would be of great value as an 
insight into the flow characteristics in the two-dimensional model but it is ultimately the 
three-dimensional flow characteristics we are concerned with. Daniel’s work was at all 
times directed by the author and reflects work previously investigated
3.6.2 Methods
At corresponding positions to the sampling points (stations) of the analytical model holes 
of a suitable size were drilled into the Perspex cover of the 2DSML. Figure 3.8 shows a 
photograph of the 2DSML as set up for pressure testing experimentation.
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The Perspex sheets were fitted onto the model with a layer o f  silicone grease between and 
securely bolted together. The yellow tubing (1.6 mm ext. diam., 1.0 mm int. diam.) was 
connected to the Perspex sheet using fitted pieces o f metal hypodermic tubing for rigidity 
securely glued into the Perspex sheet and at the other ends to a manometer. Figure 3.9 
contains a photograph o f the experimental set-up.
The procedure for pressure testing in the 2DSML was as follows:
A vacuum pump (GAST, Model 1423 10IQ Q626X. Benton Harbour M.I. USA.) was 
used to generate the airflow. The inlet o f  the pump was connected to a regulating valve 
that was used to vary the flow rate. The system had an operational range o f  0-70 lmin'1.
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The pump system was connected to the 2DSML using suitable flexible tubing; airtight 
seals were formed using jubilee clips.





Using a flow meter (SCR2, Glass precision Ltd., UK.) The airflow at the inlet was 
determined. The flow meter was calibrated prior to the experiments using a Chell™ CPD 
100 digital flow meter. The experimental work was carried out using flow rates o f  10,
30, 45, 60 and 70 1 min'1.
At each determined flow rate manometer readings were taken. When low flow rates were 
being investigated it was necessary to tilt the manometer to achieve a suitably sensitivity 
for the readings. The angles used were measured using protractor and spirit level, the 
readings were adjusted for angles during calculation.
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The results o f  the work are presented according to grouped data around each shell, this 
enables and insight into the pressure drops occurring between shells and so averages any 
positional differences in airflow intensity around each shell. Figure 3.10 shows a 
diagram o f the positions o f the pressure tapings followed by figure 3.11a  chart o f the 
grouped tapings for processing o f  the results.
3.6.3 Pressure Tapings and Zone Grouping








Figure 3.11. Chart detailing the position and grouping methods used for data analysis, 
the stated angle measurements were the variation o f  the point from vertical as detailed in 
figure 3.10 above.
Tapping No. Region Corresponding zone <J>/°
1 Throat 1 1 NA
2 Throat 2 2 NA
3 Throat 3 3 NA
4 Bifurcation-Shell 1 4 90
5 Bifurcation-Shell 1 4 20
6 Bifurcation-Shell 1 4 160
7 Shell 1-Shell 2 5 25
8 Shell 1-Shell 2 5 70
9 Shell 1-Shell 2 5 110
10 Shell 1-Shell 2 5 155
11 Shell 2-Shell 3 6 45
12 Shell 2-Shell 3 6 90
13 Shell 2-Shell 3 6 135
14 Shell 3-Shell 4 7 30
15 Shell 3-Shell 4 7 90
16 Shell 3-Shell 4 7 150
17 Shell 4-Shell 5 8 15
18 Shell 4-Shell 5 8 60
19 Shell 4-Shell 5 8 120
20 Shell 4-Shell 5 8 165
3.7 Results and discussion of Analytical and Experimental 
Pressure Testing
The results are presented graphically and contain data for both analytical and 
experimental 2DSML models. The graphs are presented to indicate the relationship 
between static pressure loss relative to atmospheric conditions (AP) and the 
corresponding zone o f  interest.
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Figure 3.12. Graph showing static pressure changes in the analytical and experimental
2DSML at 101 m in1.
Z one
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Figure 3.13. Graph showing static pressure changes in the analytical and experimental 
2DSML at 3 0 1 m m 1.
Z one








—■— Analytical — Experimental
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Figure 3.14. Graph showing static pressure changes in the analytical and experimental
2DSML at 45 1 min'1.
Z one
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Figure 3.15. Graph showing static pressure changes in the analytical and experimental 
2DSML at 60 1 min'1.
Z one
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Figure 3.16. Graph showing static pressure changes in the analytical and experimental
2DSML at 70 1 min'1.
Z one
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3.8 Discussion
The pressure as would be expected decreases as a function o f  distance from the inlet 
(Throat) through the model. Agreement between the analytical and experimental work 
becomes better at higher flow rates where experimental errors are not as large, it was 
seen that the static pressure varied around the shell zone possibly due to the positioning 
o f the outlet, i f  it were more central then the variation may have been less.
The geometric constraints o f the model causes the drop in pressure it can be seen that the 
differences are greater in all instances after zone 4 (shells). It can be said that for higher 
flow rates the analytical model is a suitable tool for the investigation o f  flow within the 
2DSML. The design o f  an analytical model for assessing the flows in the three-
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dimensional physical model would have to be far more complex however, the approach 
can be said to be appropriate.
3.9 Flow Visualisation
3.9.1 Introduction
Using water as the fluid in question the 2DSML was set up to investigate the direction of 
flow in the model. Using a dye tracer it was possible to track streak lines in the fluid and 
assess areas of particular interest such as possible impaction points (back of Throat,
Shell 1 and Shell 2).
To make the experiments as reliable as possible calculations were made to change the 
fluid from air to water and pass water through the model at comparable Reynolds 
numbers to that of the air at specified flow rates (equation 27).




p = fluid density (kgm' ), 
v = fluid velocity (ms'1), 
r) = fluid viscosity (kgm'1 s'1) 
d = characteristic length scale (m).
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Flow rates of 10,15 and 30 1 min'1 were investigated using this technique. In order to 
observe the motion of the water, the fluid was marked with a coloured dye. Observing 
the motion of the dye allowed conclusions to be drawn relating to the direction of the 
flow. There are three main conditions that a tracer used for such purpose should meet; 
neutral buoyancy, high stability against mixing and good visibility.
It was possible to inject dye into the 2DSML either as a streak in effect a prolonged 
injection of dye matching the flow of the fluid through the device or as a cloud where a 
fixed ‘dose’ of dye was injected all at once.
Investigations were made into:
• Flow rate: Q = 10 lmin'1, Q = 15 lmin'1, Q = 30 lmin'1
• Point of dye injection: Throat, or Shell 1
• Point of interest: Throat, bifurcation, shell 1, shell 2, shells 1-5
• Trace type: Streak, cloud
Figure 3.17. Adjusted flow of water (Qw) for correct representation of Reynolds number 










The experimental set-up for the flow visualisation study is shown in figure 3.18. As in 
the airflow experiments, the 2DSML was encased between two transparent Perspex 
plates. A watertight seal was made by attaching lengths o f  flexible silicon tubing to the 
edges o f  the 2DSML. Bolts were then used to securely clamp the model in place.













3.9.3 Flow Visualisation Results and Discussion
The series o f  experiments described here although not quantitative allow the viewer to 
see the pattern o f flow dispersion through the 2DSML. Once the flow properties o f  the 
2DSML are understood clearly it may be possible to investigate the flow in the three-
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dimensional model. These experiments give some insight into the flow properties o f the 
2DSML and SML.
Results are presented as a series o f stills taken from digital films made o f  the flow  
visualisation experiments. Experimental work showing streak traces show variations in 
flow characteristics as the flow rate was changed. Data for cloud injection into the model 
are shown as a function o f time at a flow rate o f  2 1 min'1.
Figure 3.19. Streak lines indicating direction o f  flow at a. 0.66 1 min"1, b. 1.00 1 min'1 
and c. 2.00 1 min"1.
a. b. c.
Discussion:
At the highest flow rate o f  2.00 1 min"1 it can be seen that the streak line becomes 
‘broken’ and variable with the flow. In each o f  the cases it is reasonable to assume that 
the flow carries the streak and it hits the back o f  the throat before it can make the 90° 
bend.
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Figure 3.20. Flow visualisation o f a ‘cloud’ moving through the 2DSML at time intervals 
(t) from t = 0 point o f  injection to t = 1.25s dispersion o f  the cloud in shell 3.
t = 0.0s t = 0.25s t = 0.50s
t = 0.75s t =  1.00s t = 1.25s
Discussion:
It is evident at t = 0.50s that the ‘cloud’ o f  dye begins to mix in shell 1. The area 
develops into a region o f turbulence as the time sequence moves on. Throughout the 
sequence it can be seen that jets are indeed formed from the holes in shells 1, 2 and to a 
lesser degree 3. As theory suggests it is likely that impaction occurs in shell 1 and the 
data seen here supports that.
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Figure 3.21. Streak lines indicating the direction o f  flow in shell 1 at flow rates o f  a. 
0.66 1 min'1, b. 1.00 1 min'1 and c. 2.00 1 min'1.
a. b. c.
Discussion:
The dye tracer here reinforces what we have seen in the data displayed in Figure 3.19. 
The dye at lower flow rates finds it way through Shell 1 to hit Shell 2. At the higher flow  
rate (c.) it is clear that the streak line hits shell 1 and mixing o f  the dye in the region 
occurs. It is proposed that (c.) represents evidence for jet impaction onto the surface o f  
Shell 1.
Possible jet impaction can also be observed on the surface o f  Shell 2 in (c.). It is noted 
however that this effect is less than seen in Shell 1.
3.9.4 General Comments
There are limitations and errors that occur in this type o f experiment. The introduction o f  
foreign matter into the flow by the method used will disrupt the body o f  flow. If the dye
84
were injected at a distance then it would become too diffused in the flow to be able to 
give a good guideline to the flow properties. It is not sufficient to view the data as 
determining turbulence in the flow, the model has manufacturing faults and external 
disturbances will play a part in influencing what we may perceive to be turbulent flow.
The experimental design and procedure were fitting for this work and provided an 
excellent insight into the mechanics and direction of the flow as functions of flow rate 
and time.
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Chapter 4 Calibration of the Shell Model Lung
4.1 Introduction
The design of the Shell Model Lung was intended to provide a model that demonstrates 
the particle deposition characteristics as seen in a human lung. The positioning, number 
and diameter of the holes in each shell allows the passage of air through the model. 
Particles are carried with the air until forces dictate their deposition at points throughout 
the model.
The SML was designed with the ‘non-ideal’ separation of an aerosol cloud as seen in the 
human lung in mind, therefore it was not envisaged that the model would or indeed 
should only collect particles by the impaction method.
It was first thought that the model could be calibrated using polystyrene latex particles 
however it was found that the method was not sufficiently accurate in that any 
evaporation would leave residue and any impurities in the water for dilution would 
results in the aerosol being less than monodisperse (Berglund and Liu, 1973).
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4.2 Creating monodisperse particles
Evaporation/Condensation Aerosol Generators produce an aerosol that is of a good 
monodisperse order (g.s.d. <1.15). The advantage of this equipment is that the operator 
may set the particle size. The size range is from about 0.1 to 8 microns, for many 
applications this range is too narrow. The aerosol material used may be non-volatile oils 
such as Di-Octyl Phthalate (DOP) or Di-Ethylhexyl Sebacate (DEHS) or a solid such as 
Methylene Blue. It has been shown that a solution of Methylene Blue: Liquid Solution 
(1:2000) (Liquid solution 50:50 ethanol: water) produces spherical dry particles of 
Methylene Blue after aerosolisation using a VOAG (Berglund and Liu, 1973). A variety 
of methods could be used to cover a wide range of particle sizes (Marple et al, 1991).
4.3 Vibrating Orifice Aerosol Generator
4.3.1 Description
The equipment used to calibrate the SML was the Vibrating Orifice Aerosol Generator 
(VOAG). The generator is based on the fact that liquid jets are unstable and break-up. If 
a liquid jet is produced it will naturally break-up into droplets of varying size. If the 
breaking point of these droplets is carefully controlled then the droplets produced will be 
theoretically uniform. To prevent these monodisperse droplets from coalescing and 
coagulating the droplets must be dispersed and diluted, the VOAG performs all these 
operations. Constant airflow during drying should result in spherical particles (Asking 
and Olsson, 1997).
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Altering the diameter of the orifice allows a wide size range of droplets to be produced by 
the generator. There is a range of orifices available from 10pm to 100pm. The size of 
the droplets may be finely tuned by varying the concentration of the liquid jet (a non­
volatile solute in a volatile solvent). Theoretically using a VOAG with a non-volatile 
solvent it should be possible to calculate the particle size of solute produced. The VOAG 
is extremely difficult to operate and many factors can affect differences in resulting 
particle size therefore it is always necessary to size the particles using a reliable method.
It is also essential that dispersion air is used to prevent not only coalescing of the particles 
but also to reduce electrostatic effects. Using a radioactive source may also reduce these 
effects.
The method of calibration selected was governed by the time remaining for the study. 
Unfortunately due to these time constraints the work could not be carried out at the 
University. An attempt was made to produce some monodisperse particles using the 
vibrating orifice aerosol generator (VOAG) but it was felt that this would take up too 
much valuable time. The instrumentation is particularly delicate and difficult to master 
so Dr Ian Marshall and his team carried out calibration of the SML at AEA (Culham). A 
description of the instrumentation and methods follow.
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Figure 4.1 Schematic diagram o f the break-up o f  a liquid jet as occurs when creating 








The theory o f cylinder break-up has been derived (VOAG operating manual). The 
consideration of surface energy has contributed to the derivation of a minimum 
wavelength (distance between disturbances) for a disturbance to be unstable on a liquid 
cylinder of infinite length.
Xmin = TlDj (28)
Dj =  liquid cylinder (Jet) diameter (m)
For an inviscid, incompressible jet the optimum wavelength was derived as:
AoPt = 4.508 Dj (29)
It was determined experimentally that varying X within the following limits could 
produce uniform droplets:
3 .5Dj<A,<7Dj  (30)
As energy is conserved a minimum liquid velocity required to form a liquid jet from a 
capillary tube was derived.
Vj, min = ( 8 cj / pDj)1/2 (31)
o = surface tension N m'1 
p = density of the liquid (g cm-3)
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Consequently uniform droplets may only be generated when maintaining both:
Vj > Vj, min (32)
and
3.5 Dj < (Vj / f ) , 7Dj (33)
f  = frequency of crystal vibration ( X /Vj) (Hz)
Since one droplet is produced after each cycle of disturbance, the droplet volume is given 
by Q / f, and the droplet diameter by:
Dd = (6Q/7tf),/3 (34)
Q= liquid flow rate (cm3 min'1)
The droplet diameter can theoretically be calculated precisely using the above equation. 
When the liquid solution is forced through the orifice and the volatile solvent are allowed 
to evaporate from the droplets, non-volatile particles of the solute are obtained. The 
particle diameter is given by:
Dp = C1/3 Dj (35)
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C = volumetric concentration of the solute in the solution (v/v)
Dd = initial droplet diameter calculated from equation 19 (m)
An error in the calculation will occur if impurities are present in the solvent, this may be 
estimated but the inherent errors in the VOAG and during its use means that each aerosol 
produced will be different even when another batch of the same liquid is run through the 
generator using the same settings. It is unfortunately necessary that each time an aerosol 
is produced it must be analysed by a specialist aerosol particle sizer (APS TSI inc. 33b 
s/n 196 in this calibration exercise). This was one of the many reasons for the calibration 
work being carried out by AEA, the equipment and expertise in using these system was 
far superior to any work that could have been achieved at the University laboratories.
The use of an APS would be essential to this type of calibration. The APS gives an 
accurate result quickly and efficiently.
When producing particles using a VOAG it is essential that the surrounding environment 
is very clean and dust free. This factor was overcome to some extent at AEA by covering 
the orifice set-up so it didn’t get blocked as easily or frequently. Dust and fibre particles 
can block the orifice. Once the orifice becomes blocked it must be carefully cleaned in a 
detergent solution and then rinsed in the solvent. It is easy to see using a light 
microscope for example that the orifice is clear of debris.
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4.3.3 Instrumentation set-up at AEA
The set-up o f the VOAG at AEA was modified to give an optimum output and least 
possible variation in particle diameter. The orifice may also become blocked if the 
solvent is not free of contaminants therefore it is essential that the liquid feed be 
thoroughly filtered before use. The VOAG at AEA included a pump from a HPLC 
machine to drive the liquid through the orifice. The pumps are dampened and had a 
much smoother action than the pump supplied with the VOAG. This in effect ensures 
that the liquid flow rate (Q) was kept constant according to equation 19 the diameter of 
the droplet produced had a lower GSD which means the aerosol produced was more 
reliably closer to being monodisperse.
4.4 Equipment
Figure 4.2 Analytical equipment used during the calibration of the SML
Type Certification
Spectrophotometry Pye Unicam PU8600 
S/N 342527
ATI Unicam 200226 
19/05/00




Balance Sartorius B3100P 
S/N 40010153
SMK Balance Services 06850 
07/12/99











Particles of Methylene blue were produced at the VOAG orifice. Particles of 
approximately 10pm, 7pm, 5 pm and 4pm were generated to cover the expected range of 
deposition in the SML. The VOAG was set up at the top of a rig of approximately 3 metres 
in height. Once the particles had been produced they were dispersed and diluted using air 
and collected into a drying column. The drying column extended from the orifice to the 
sampling level. As the particles were released from the column they were completely 
dry. This is essential if  the APS is to give a reliable result. The particles are drawn 
through the APS and if  they are not completely dry their diameter will change as they 
travel through the sizing apparatus due to evaporation and give a result that is variable 
and inaccurate.
During the drying stage it is usually advised that a radiation source is used to reduce the 
electrostatic properties of the particles unfortunately the radiation source wasn’t available 
at the time o f the calibration procedure. At this point the particles were sized using the 
APS.
The vacuum pump was set at a flow rate of 30 1 min'1 through the SML using the 
Hastings flow meter and adjusted for temperature as read from the Digitron thermometer, 
according to a calibrated scheme. At the exit point of the column a short piece of tubing 
was used to connect the column to the SML throat. The sampling time varied between 2 
and 10 minutes depending upon the size of the particles and therefore the production rate. 
After each experiment the SML was washed as in section 5.4.5 using Methanol, the
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washings were weighed and the concentration of Methylene Blue detected using the 
spectrophotometer. The mass of Methylene Blue was then calculated. For each 
experiment the mass percentage collected on each stage and the collection efficiency for 
each stage were calculated and plotted against the recorded particle MMAD.
4.6 Results
The first part of the results shows the mass percentage deposition in each stage according 
to particle MMAD. This gives an indication of how each shell behaves in relation to the 
rest of the model when an aerosol of known aerodynamic diameter deposits. The 
presentation of these graphs is similar to the presentation of the graphs in chapter 5 where 
the percentage of ‘Drug Recovered’ from a commercial inhaler is plotted as the y-axis. 
The relationship between aerodynamic diameter and deposition in the SML will be 
investigated according to these results. The mass percentage graphs do not indicate 
deposition by impaction or any other mechanism.
The collection efficiency for each stage will be presented in the second part of these 
results. Collection efficiency is an indication of the collection properties of the stage. If 
the line passes through 50% we can say that the stage will collect particles by impaction.
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Figure 4.3 Particle diameters generated during run 1 and run 2
Aerodynamic Diameter 
lim





Generation o f the particles by a VOAG are not sufficiently accurate to be able to quote 
the values to 2 decimal places therefore the raw data were rounded up to 1 decimal place. 
The mean diameters are quoted to 2 decimal places where appropriate. The particles are 
completely dry when entering the APS they are stable and so do not change in size 
therefore the quoted diameters are of a good accuracy.
The results are presented as graphs where appropriate discussions will indicate actual 
values. Graphs show actual data collected as scatter points and the mean value as a line 
through those points. Unfortunately the economic restrictions on this project allowed 











4.6.1 Mass percentage/particle MMAD for each stage
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Figure 4.6. Graph showing mass percentage of Methylene Blue collected in the Throat
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Figure 4.8. Graph showing mass percentage of Methylene Blue collected in Shell 3,
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4.6.2 Collection efficiency/ particle MMAD for each stage
Collection efficiency was plotted against the aerodynamic diameter o f  the monodisperse 
particles generated and then tested in the SML. As discussed in section 1.6 the collection 
efficiency defines i f  impaction occurs and how the cut point curve fits the ideal cut point 
curve. If the graph passes through the 50% then it can be said that impaction occurs. The 
variation o f  the graph from ideal means particles that are undersize get collected and 
particles oversize will escape collection. Graphs show actual data collected as scatter 
points and the mean value as a line through those points.
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Even though the graphs presented in figures 4.11 and 4.12 above do not go through 50% 
it was calculated that the 50% cut point in the throat would be approximately 19pm. The 
following graph figure 4.13 presents the data for the throat and bifurcation together. The 
data was simply added together to give the collection efficiency for both regions. 
Throughout the results presented the throat and bifurcation were washed together and 
displayed as one stage.
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Figure 4.13 Graph showing, collection efficiency in the Throat and Bifurcation for
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Further calibration must be performed before any such extrapolation can be said to be 
valid. The summed data when extrapolated shows a (theoretical) 50% cut point at 19pm. 
The cutpoint at the throat when testing a commercial inhaler depends very much upon the 
ballistic qualities o f  the aerosol cloud exiting the inhaler mouthpiece.
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The collection efficiency curve for Shell 1 passes through the 50% value indicating that 
impaction is occurring. For a sharp cut o ff Hinds (1999) states that the Reynolds number 
should be between 500 and 3000 from equation (24) the calculated Reynolds number was 
found to be 3511. The theoretical value for the cut point was found to be 7.75pm. The 
experimentally determined cut point was 7.2pm. A number o f  factors contribute to this 
discrepancy. The shell acts as the collection site and as it contains holes much larger than 
the particles seen at this stage it is possible that they simply follow the airstream through 
the holes in the shell. Most o f the particles collected on the back plate result from air
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mixing as the jet from the bifurcation reaches Shell 1. Due to the design o f  the model this 
is inevitable and further design modifications will be discussed in section 6.6.
The collection efficiency curves for Shell 2, Shell 3, Shell 4 and Shell 5 do not pass 
through the 50% value. It is clear that the shells are collecting particles but as this 
analysis only defines impaction the criteria is not met. The collection o f  particles may be 
taking place due to gravitational settling or diffusion.
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As previously discussed collection on the back plate is dependent on the air mixing or 
turbulence created from the air jet exiting the Bifurcation. Peak collection efficiency 
occurs at around 8pm when the flow rate is at 30 1 min'1. It would be expected that this 
value would increase at higher flow rates as the airflow becomes more turbulent in the 
shells.
4.7 General Discussion
The experimentally determined cutpoint at shell 1 (7.2pm) was found to be in good 
agreement with the calculated value (7.7pm and 10.2pm) (section 2.3.13 and 2.3.14). 
There are a number of possible reasons for the discrepancy:
• Geometric factors
o Impaction onto a curved surface 
o Angle of flow from bifurcation 
o Direction of flow through the model
• Calculated Re could be less than actual Re
o Discrepancies in model geometries 
o ‘Roughness’ inside bifurcation may increase turbulence
• High Re may result in errors
o High turbulence and mixing may prevent impaction 
o Re>3000 therefore cutpoint dependent on Re (Marple et al 1998) 
Although the model was not intended to collect particle by impaction it has been 
shown that this method of particle deposition does occur but only in Shell 1.
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It would have been interesting to calibrate the model at various flow rates. DPIs 
require greater inspiratory effort by the patient and current impactors were not 
designed to operate at such high flow rates (around 601 min'1). The Andersen 
cascade impactor has been modified to operate at 601 min'1 (Nichols et a l, 1998) to 
give as good a range of cut points as the regular ACI by inserting a stage above stage 
0 and removing stage 7. A low flow rate would be desirable to simulate the 
respiratory effort seen in infants, children and the severely respiratory impaired 
patient. A low flow rate version of the Marple-Miller impactor was devised (Olson et 
al, 1998) to operate at 4.9 1 min'1 or 12 1 min'1. It was found to be of a sufficiently 
high standard and met the objectives set out for the original impactor.
It is desirable for in vitro devices to be capable of performing well at several different 
flow rates so that the whole range of aerosol generating devices may be tested. In 
particular there are problems when sizing nebulised aerosols using impactors or 
impingers at their regular flow rates for particle sizing (Dennis, 1998 and Stapleton 
and Finlay, 1998). Using a ‘breathing pattern’ when calibration the SML would 
allow the device to be used for nebuliser testing. It may then be possible for the 
model to be used to assess environmental pollution.
The calibration has shown that the calculations used to determine the theoretical cut 
point were appropriate. Further calibration would be of great benefit however, 
economic and time constraints upon this work left little scope for improving the 
situation.
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Chapter 5 Data collection and Results
5.1 Materials
This chapter describes the materials and methods used to characterise aerosol clouds. A 
summary of aerosol devices used and their contents is followed by a description of the 
analytical methods. The general methods for using both the Shell Model Lung and the 
Andersen Cascade Impactor are described here.
5.1.1 Formulations
Figure 5.1 Table of commercial products used
Product Type Drug Batch / Expiry Supplier
Ventolin CFC MDI Salbutamol BN: M62 
EXP: 05/2001
Allen & Hanburys Ltd 
Greenford,
UB6 0HB.
Airomir HFAMDI Salbutamol BN: 97102C 
EXP: 09/99
3M,
3M Healthcare Ltd, 
Loughborough, LEI 1 
1EP.
Airomir HFAMDI Salbutamol BN: 9BD028A 
EXP: 04/2002
3M,
3M Healthcare Ltd, 




HFAMDI Salbutamol BN: 10483695 
EXP: 05/2000
Allen & Hanburys Ltd 
Greenford,
UB6 0HB.
Bricanyl CFC MDI Terbutaline BN: ZG 347 
EXP: 07/2001
Astra Pharmaceuticals 
Ltd, Kings Langley 
Hertfordshire, WD4 8DH
Bricanyl Turbuhaler Terbutaline BN: 351037F 
EXP: 05/2002
Astra Pharmaceuticals 
Ltd, Kings Langley 
Hertfordshire WD4 8DH.
Ventolin Diskhaler Salbutamol BN: D013788 
EXP: 10/2003




Each formulation was primed before use (5 shots to waste) and weighed before, during
and after each actuation.
5.1.2 Solvents
• Distilled water
• Methanol (washing and during VOAG) Supplier: BDH Laboratory Supplies, 
Poole, BH15 1TD.
5.1.3 Equipment
Compressor: Novair Compressor 88862 Type MK 3.500.80.35 Intrasurgical Ltd. Crane 
House, Gould Road, Twickenham, Middlesex TW2 6RS.
Pump: GAST, Model 1423 101Q Q626X. Benton Harbour M.I. USA.
Flow Meter: SCR2, Glass precision Ltd., UK.
Digital Flow Meter: Chell™ CPD 100 digital flow meter (Vectura Lab Meter 4 Serial 
Number: 00646 00001).
Filter paper: Gelman Sciences Type A/E Glass 76mm Lot: 80933. 600 South Wagner 




Figure 5.2 Mechanisms of Fluorescence
Radiationless
Transition













An organic molecule will absorb radiation o f certain wavelengths to jump to an excited 
state. Some o f  the absorbed energy is lost on vibrational relaxation (radiationless 
transition to the lowest vibrational level take place in the excited state). The molecule 
eventually returns to the ground state and emits energy which; is termed “fluorescence”. 
If radiationless transition to the triplet state takes place, the molecule emits optical energy 
when returning to the ground state. The optical energy emitted is termed 
“phosphorescence”.
Phosphorescence persists for 10^ seconds and fluorescence usually for 10'8 to 10'9 
seconds.
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The ratio of the optical energy absorbed by a substance to the total fluorescence energy 
emitted from the substance is called “quantum efficiency”. Generally if a sample has 
high quantum efficiency it will have a high fluorescence emission.
For a dilute sample, the intensity of fluorescence is expressed by the following formula:
F = KI0cle<p (36)
F= intensity of fluorescence
K= instrumental constant
Io= intensity of excitation radiation
c = concentration of substance
1 = optical path length of cell
8= absoptivity o f substance
cp= quantum efficiency of substance
Analysis by fluorescence has advantages over absorption methods. If a sample has a 
transmittance of 99% and the blank has a transmittance of 100%, an error factor, which is 
unavoidable in absorbance measurement, must be considered in both cases. The error 
factor is 0.1%, therefore,
Transmittance o f blank solution = 100.0 ±0.1%
Transmittance o f sample = 99.0 ± 0.1 %
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Difference = 1.0 ± 0.2% (value depending upon sample concentration)
In this example an error as high as ±20% is involved in the analysis of samples with low 
absorbance, as is the case for salbutamol.
In fluorescence analysis, differences from the zero level generally correspond to sample 
concentration, as follows,
Output signal level in
sample measurement =100 ±0.1
Value corresponding to blank = 0 ± 0.2
Difference = 100 ± 0.2 (proportional to sample concentration)
The examples show that fluorescence analysis is based upon principles that assure low 
error percentages even in the case of low concentrations. At very low concentrations 
error values are enhanced but it can still be said that fluorescence allows measurements of 
concentrations a factor of 10'3 below those measurable by the absorption method.
The analytical data obtained from an absorption spectrophotometer is the absorption 
spectra only however, in a fluorescence spectrophotometer an excitation and emission 
spectra are obtained.
There are some disadvantages associated with the use of fluorimetry; the intensities are 
reduced 1 to 2% as the sample temperature rises by 1°C. Certain samples are chemically 
affected by excitation light. Rayleigh scattering may appear at the same wavelength as
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the excitation light, caused by electromagnetic radiation emitted from the particles’ 
electrons. The electrons are in an intense alternating field caused by the electric and 
magnetic components of the radiation. Raman scattering appears at longer wavelengths, 
it occurs if  one or more of the normal modes of vibration of a molecule involves changes 
in the polarizability. The scattered radiation contains this vibrational frequency 
superimposed upon the frequency of the incident radiation. Both forms of scattering 
appear on the spectra as peaks.
Samples of high concentrations are associated with various error factors:
• Excitation light is absorbed at the cell inlet, which prevents the excitation light 
reaching the cell centre.
• Molecules may interact causing “concentration extinction”
• The fluorescence may be reabsorbed if the excitation and emission wavelengths 
overlap
It is very important that the cell is not contaminated. It is possible that the sample may 
adhere to the wall of the cell and if  not washed properly the cell will retain the sample.
To reduce the errors involved with fluorimetry, samples must be of a low concentration 
(typically 0.01 to 5.00 pg ml'1). Each time the fluorimeter is switched on it must be 
calibrated, due to a small drift in the relative intensity value, unfortunately inherent in the 





Equipment: Hitachi, model F-2000 (251 -0005) Fluorescence Spectrophotometer
Lamp: Hitachi Long -life Xenon lamp UXL-1157 583769 
10mm quartz cell, Merck 307371401 Far U.V. silica -  fluorescence. 
The light source was allowed to stabilise for at least 20 minutes before the first sample 
was measured, after the instrument was calibrated the analysis of the samples could 
begin.
5.3.1 Salbutamol -  instrument settings and appropriate results 



















Spectrofluorimetry was used as the method of analysis as it is more sensitive test than 
Ultra Violet (UV) analysis via High Performance Liquid Chromatography (HPLC) (as
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discussed above) when analysing salbutamol. It is also a quicker less wasteful method 
than HPLC as no mobile phase or internal standard is necessary.
A calibration profile of salbutamol was undertaken to ensure experimental procedure was 
correct and a linear relationship between concentration and relative intensity of the signal 
occurred. Two stock solutions of around 50pg ml"1 were prepared, a series of dilutions 
were made to produce concentrations in the range of 0.5pg to 5pg. The instrument 
automatically produces a calibration curve and correlation coefficient to three decimal 
places. To check these values the data points were entered into Sigma Plot 4.0 (1997 
SPSS Inc.) the graph package used throughout this work to check the linearity. As 
previously stated the spectrofluorimeter requires calibrating each time it is switched on, 
to ensure reproducibility it was necessary to achieve a calibration correlation coefficient 
of 0.999 read from the instrument. The instrument measures relative to the calibration 
curve. After the calibration procedure the instrument was blanked using the solvent then 
each unknown solution was tested and its relative intensity as calculated by the 
spectrofluorimeter was recorded. From this the percentage of drug delivered into the 
device was calculated.
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Figure 5.4 Typical values when assaying Salbutamol using the method outlined above
Stock Gradient Intercept r 2 ..........
Mean Value St Dev Mean Value St Dev
Stock 1 58.05 0.212 9.525 0.672 0.9998
Stock 2 57.30 0.566 9.125 0.403 0.9997
5.3.2 Terbutaline -  instrument settings and appropriate results 














Figure 5.6 Typical values when assaying Salbutamol using the method outlined above
Stock Gradient Intercept ....................r2 - ................
Mean Value St Dev Mean Value St Dev
Stock 1 24.44 0.49 5.55 0.52 0.9997
Stock 2 25.02 0.33 4.45 0.66 0.9998
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5.4 Statistical analyses
Throughout this work statistical comparisons were made between commercial inhalers 
and the properties of the SML. During the calibration work described above values of 
linearity were found in order to be confident of results collected. The sections below 
summarise the statistical models used (Weiss, 1995)
5.4.1 Standard deviation
Variations from the mean in a group of data are described by the standard deviation. It is 
calculated by:
where:
s = standard deviation 
n = sample size
The standard deviation of samples was found using Minitab 12.1.
5.4.2 Coefficient of determination (r2)
The coefficient of determination describes for the purpose of the calibration work the 
accuracy of the standard solutions, r2 describes how ‘straight’ a calibration curve was. 
After running the standard solutions on the fluorimeter the instrument drew a graph of
(37)
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intensity against concentration. A ‘calibration’ function of the instrument then calculated 
the value of the coefficient of determination. The instrumental determination was used in 
each case after it was ensured (also using Minitab 12.1) to be at least 0.999.
5.4.3 Analysis of variance (ANOVA)
This statistical method can compare thee means of more than two sets of data. One-way 
ANOVA compares the means of populations with respect to one factor. Two-way 
ANOVA similarly compares the means with respect to two factors. Many values are 
calculated using this method, probably the most useful is the P value and to a lesser 
extent the F statistic. The method was carried out using Minitab 12.1
The P value is the probability of the populations being similar therefore the close the P 
value is to 0 the less likely the data are related.
The F statistic describes the variation between the sample means. Large F values show 
the population means are not equal
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5.5 Experimental procedure -  Shell Model Lung
5.5.1 Assembly of the incomplete SML
Filter: A filter was inserted into a filter holder on the inside of the cylinder over
the outlet.
Bifurcation: The bifurcation was carefully screwed into the back plate, it was necessary
to take care with this procedure as the metal can deform.
Shell 1: The bifurcation side of the model was rested on the bench and shell 1 was
screwed into position into the back plate, the holes aligned in one 
orientation only which is clearly marked on each shell and on the back 
plate.
Shell 2: As above.
Shell 3: As above.
Cylinder: A filter was placed over the outlet hole in the interior of the cylinder the
filter holder was firmly screwed into position keeping the filter in place. 
The cylinder was placed over the shells and screwed into the back plate.
Throat: Once the model was repositioned on its base a tight seal was made when
the throat was pushed firmly onto the opening of the bifurcation.
Mouthpiece: A mouthpiece was then fitted to the inlet of the throat. It was ensured that 
for each type of device tested, a mouthpiece with a good tight fit was used.
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5.5.2 Assembly of the SML
Filter: A filter was inserted into a filter holder (Pari) situated after the outlet pipe.
Bifurcation: The bifurcation was carefully screwed into the back plate, it was necessary
to take care with this procedure as the metal can deform.
The bifurcation side of the model was rested on the bench and shell 1 was 
screwed into position into the back plate, the holes align in one orientation 





Once the model was repositioned on its base a tight seal was made when 
the throat was pushed firmly onto the opening of the bifurcation. 
Mouthpiece: A mouthpiece was then fitted to the inlet of the throat. It was ensured that 
for each type of device tested, a mouthpiece with a good tight fit was used.
5.5.3 Settling time
Once the SML was assembled as described above a vacuum pump and timer device were 
fitted to the outlet pipe of the model. At this stage the flow rate was tested at the throat 
using a calibrated float type flow meter. A timer was set to the required time and the 








Each inhaler was delivered into the device according to the manufacturers instructions. 
Once the required amount of drug had been delivered into the SML a period of ten 
minutes was timed to allow any settling to take place then the device was dismantled. 
Ten minutes was found to be sufficient according to the Stokes settling rate (Hinds,
1999):
v = g a2 (pi-p2)/18r| (38)
Where:
v = rate of sedimentation (m s'1)
a = particle radius (m)
pi = particle density (kg m '3)
p2 = density of the medium (kg m'3)
g = gravitational constant (m s*2)
r| = viscosity of the dispersion medium (N s m'2)
v = 9.807 x rno  x io 'V i x n o 3 - 1 .2 0 5 )
18 x (1.822 x 10'5) (39)
v = 3.0 x 10'3 m s'1 (40)
This is equivalent to 3mm s'1, therefore in 10 minutes a particle 10pm in diameter would 
fall 1.8m over nine times the total height of the device. A particle of 1pm would
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therefore fall 1.8cm in 10 minutes. The maximum distance between shells is 2cm for
particles of 1pm 10 minutes was thought sufficient time to allow particle settling.
Deposition on the model was analysed as follows.
5.5.4 Washing procedure -  incomplete SML
Distilled water was used as the solvent for all washings for each inhaler device unless
otherwise stated.
1. The cylinder was unscrewed and the filter holder removed. The interior of the 
cylinder was washed into a 100ml volumetric flask.
2. The filter was removed from the filter holder and placed into a beaker containing the 
solvent this was then sonicated for 2 minutes the filter and solvent washings were 
collected into a 100ml volumetric flask
3. The mouthpiece and device were both washed into a 250ml volumetric flask, if the 
inhaler device was not detachable then the mouthpiece was washed into a 100ml 
volumetric flask.
4. The throat was detached and washed then the bifurcation was unscrewed and washed 
both washings were collected into one 250ml volumetric flask
5. Shell 3 was unscrewed and placed into a large funnel and washed into a 100ml 
volumetric flask.
6. Shell 2 was unscrewed and placed into a smaller funnel and washed into a 100ml 
volumetric flask.
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7. Shell 1 was unscrewed and placed into the smaller funnel and washed into a 100ml 
volumetric flask.
8. The back plate was then washed through the large funnel into a 50ml volumetric flask
5.5.5 Washing procedure - SML
Distilled water was used as the solvent for all washings for each inhaler device unless 
otherwise stated.
1. The filter was removed from the filter holder and placed into a beaker containing 
the solvent this was then sonicated for 2 minutes the filter and solvent were then 
washed into a 100ml volumetric flask
2. The mouthpiece and device were both washed into a 250ml volumetric flask, if 
the inhaler device was not detachable then the mouthpiece was washed into a 
100ml volumetric flask.
3. The throat was detached and washed then the bifurcation was unscrewed and 
washed both were collected into one 250ml volumetric flask.
4. Shell 5 was unscrewed and washed into a 100ml volumetric flask.
5. Shell 4 was unscrewed and placed into the large funnel; the washing procedure 
was done with great care as the small holes in this shell caused the spray to 
misdirect on occasions. This shell was washed into a 50ml volumetric flask.
6. Shell 3 was unscrewed and placed into a large funnel and washed into a 100ml 
volumetric flask.
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7. Shell 2 was unscrewed and placed into a small funnel and washed into a 100ml 
volumetric flask.
8. Shell 1 was unscrewed and placed into a small funnel and washed into a 100ml 
volumetric flask.
9. The back plate was then washed through a large funnel into a 50ml volumetric 
flask
After the washing procedure each stage of the model was rinsed in Methanol to ensure it 
was clean grease free and was then left to dry. The model was ready to reassemble once 
it was completely dry. Results chapter (5) illustrates the work done in the 
characterisation of various inhaler devices during this study. Where any methods were 
changed or slightly altered from that shown above they are clearly stated. As the model 
is a novel device it was sometimes necessary and interesting to investigate these 
alterations.
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5.6 Experimental procedure - Andersen Cascade Impactor
5.6.1 Physical description
The Mark IIACI contains 8 stages it separates an aerosol cloud into discreet size 
fractions. Stages 0 and 1 both have 96 orifices arranged radially around the stage. These 
stages have collection plates containing holes of 22.2mm diameter in their centre to allow 
airflow through the centre. Stages 2 to 6 all have 400 orifices arranged in a circular 
pattern around each stage. Stage 7 contains 201 orifices again arranged radially around 
the stage. The collection plates of stages 2 to 7 have no holes in them. The collection 
plates sit on small props on the top of the stage directly below. This allows the air to 
flow around the collection plates and contributes to the separation mechanism (Graseby -  
Andersen Inc., 1985). The collection plates were at all times handled using tweezers.
5.6.2 Assembly
Filter: A filter was placed in the filter holder and an o-ring was positioned to hold
the filter directly over the area of flow 
Stage 7: A collection plate was placed on the filter holder and Stage 7 positioned
above this.
Stages 6 to 0: These collection plates and stages were assembled as for Stage 7 
Adapter: The adapter was fitted above Stage 0 and the closing springs were attached
at the indented points.
Throat: A USP throat as specified was push-fitted onto the adapter.
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Mouthpiece: A mouthpiece was then fitted to the inlet of the throat. It was ensured that 
for each type of device tested, a mouthpiece with a good tight fit was used.
5.6.3 Washing procedure
All washings for each inhaler device were done using distilled water as the solvent unless
otherwise stated
1. The mouthpiece and device were both washed into a 250ml volumetric flask, if the 
inhaler device was not detachable then the mouthpiece was washed into a 100ml 
volumetric flask.
2. The throat was detached and washed then the adapter was removed from the impactor 
and washed both washings were collected into a 250ml volumetric flask.
3. Stage 0 was removed and washed its collection plate was the removed and washed, 
all washings were collected into a 100ml volumetric flask.
4. Stages 1 to 7 were washed according to the procedure outlined above in point 3.
5. The filter was removed from the filter holder and placed into a beaker containing the 
solvent this was then sonicated for 2 minutes the filter and solvent washings were 
collected into a 100ml volumetric flask.
After washing the impactor each component was rinsed with methanol to ensure it was
clean and grease free. The ACI was then left to dry before reassembling.
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5.7 Results
Throughout the work aerosol performance in the SML is described as the % Drug 
Recovered:
% Drug Recovered = Mass of drug detected in stage(s) / pm
Total mass of drug detected / pm x 100 (41)
This equation was applied for each stage or interval as required. Aerosol performance in 
an ACI is described either as above for each stage or as the ‘Fine Particle Fraction* FPF.
It is convention to describe the FPF as the drug collected in stage 2 to filter, expressed as 
a fraction or mass of the dose as collected in the device (excluding the actuator and 
mouthpiece). Commercially available inhalers were used throughout the work as they are 
widely available and well characterised by both the manufacturer and in most cases by 
other researchers. The purpose of the results presented here is to compare the properties 
of the SML with the ACI when analysed under similar laboratory conditions.
In the majority of the work presented here metered dose inhalers were used to assess the 
SML. MDI’s are widely prescribed, as they are relatively inexpensive and suitable for 
the majority of patients. The drug is formulated as a solution or suspension. The 
formulation may also contain solvents, cosolvents and propellants. Significant co­
ordination problems for patient groups such as the elderly and children make this dosage 
form less acceptable. It is important that each actuation is well co-ordinated with the 
patients breathing or the dose may not be inhaled fully or even at all. It was shown that
in an in vitro model (Gradon, 2000) perfectly synchronised actuation and inspiration 
leads to better ‘tracheal’ penetration by particles (< 100pm).
For improved patient co-ordination Easi Brethe™ devices may be used, these self-actuate 
when the patient’s inspiratory effort is at an optimum point. The devices were found to 
improve particle deposition after the model trachea in Gradon’s in vitro device (Gradon,
2000) in comparison with MDI’s. It is though this would be due to better co-ordination, 
as the device is not reliant on patient thought and action just patient breathing. The Easi 
Brethe™ device was not investigated.
The propellants traditionally used in MDI’s were chlorofluorocarbons (CFC’s); these 
chemicals are responsible for the depletion of the ozone layer. More than 100 countries 
that signed the Montreal Protocol have banned the production of CFC’s. The new 
propellants used in MDI’s are hydrofluoroalkanes (HFA’s) (Hickey, 1992). Some 
problems including loss of internal pressure, leakage of the propellant, poor solvency 
properties and patents on new technologies (Howlett, 1998) are obstacles, these have 
been overcome by the development or the first HFA inhaler Airomir™ (Leach, 1996) a 
formulation containing salbutamol.
128
5.8 Initial Incomplete’ model
5.8.1 Airomir at 30 1 min'1
A comparison of intra-batch variability of Airomir™ was undertaken. The incomplete 
SML was used to test six cans. The cans of Airomir™ were taken from the same batch 
and tested at 30 1 min'1 and 60 1 min’1. In each case 10 actuations were used to load the 
incomplete SML. The experiment was carried out as described in section 5.4.1 and 5.4.4,
Figure 5.7 Percentage drug recovered in the incomplete SML tested at 30 1 min'1 using 
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Figure 5.8 Percentage drug recovered in the shells and cylinder incomplete SML tested
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Figure 5.9 Percentage drug recovered in the incQmplete SML tested at 30 1 min'1 using 
Airomir™ (n=9, errors are s.d.)
Stage % Drug Recovered s.d.
AM 25.7 1.6
TB 46.7 4.2
Shell 1 1.8 0.4
Shell 2 1.5 0.3





Over 72% of the recovered drug was retained in the actuator mouthpiece and throat. The 
total amount of drug recovered in the shells and cylinder (figure 5.7) was 8.2%. 
Unfortunately 19.4% o f the recovered drug was found in the filter. The problem here 
seems to be that a great deal of drug is being carried through the entire model without 
much aerosol cloud separation in the shells.
To improve the performance of the model it was decided to run the vacuum pump at 60 1 
min'1. This increase in flow should have the effect of increasing the momentum of each 
particle in the aerosol cloud. Assuming that deposition by impaction takes place in some 
stages of the model, deposition should increase, favourably altering the deposition 
profile.
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5.8.2 Airomir at 6 0 1 min'1
Figure 5.10 Percentage drug recovered in the incomplete SML tested at 601 min’1 using 
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Figure 5.11 Percentage drug Recovered in the shells and cylinder of the incomplete SML 
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Figure 5.12 Percentage drug recovered in the incomplete SML tested at 60 1 min’1 using
Airomir™ (n=6, errors are s.d.)
Stage % Drug Recovered s.d.
AM 18.7 0.8
TB 35.2 2.9
Shell 1 5.3 2.0
Shell 2 3.2 1.2




Over 50% of the recovered drug was left in the actuator, mouthpiece and throat. This is 
an improvement on the situation at 30 1 min'1. The aerosol cloud was deposited in the 
shells and cylinder region more effectively at this flow rate. The total % drug recovered 
in the shells and cylinder was 15.9%. However, the increase flow rate seems to have 
made a marked difference to the quantity of drug pulled through the model and deposited 
onto the filter. The problems encountered at the previous flow rate have become worse 
as have the errors associated with drug deposition. Although the drug collected in the 
shells and cylinder has increased the drug collected by the filter should have decreased if 
all the shells were acting as an impaction collecting system. The drug particles seem to 
have been pulled directly through the model without having the chance to deposit by 
other mechanisms as a result of the higher flow rate. An assessment of the performance 
of a Ventolin™ MDI was then made at the higher flow rate to compare the findings with 
the investigation discussed here.
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5.8.3 Ventolin at 60 1 min'1
An experiment was carried out to assess the qualities of Ventolin™ in the incomplete 
SML. The procedure outlined in section 5.4.1 and 5.4.4 was followed.
Figure 5.13 Percentage drug recovered for each Stage of the incomplete SML at 
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Figure 5.14 Percentage drug recovered in the shells and cylinder of the incomplete SML 
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Figure 5.15 Percentage drug recovered in the incomplete SML tested at 60 1 min 1 using
Ventolin™ (n=5, errors are s.d.)
Stage % Drug Recovered s.d.
AM 12.3 1.2
TB 50.6 3.2
Shell 1 3.4 0.8
Shell 2 2.0 0.4




Less drug has reached the shells with the Ventolin™ formulation than the Airomir™ 
MDI. This implies that the formulation contains coarser particles that have been 
deposited by impaction (in the throat).
The total % drug recovered in the shells and cylinder was 8.6%. A large percentage of 
drug was also being recovered from the filter with this formulation.
The large deposition of drug in the filter seen here gave an ideal opportunity to 
investigate if distilled water or methanol would be a better solvent using this formulation 
at this flow rate.
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5.8.4 Suitability of solvents
The experiment was carried out as in section 5.4.1 and 5.4.4 apart from when the washing 
procedure was undertaken the solvents used were, distilled water only, distilled water for 
the metal parts and methanol for the filter and methanol only. This investigation was 
undertaken to establish whether methanol would be a more suitable solvent for washing 
the SML to remove deposited salbutamol and if  the benefits would outweigh the expense 
and waste management problems associated with methanol.
Figure 5.16 Percentage drug recovered in the outer stages o f  the incomplete SML tested 
at 60 1 min'1 using Ventolin™ (lot: M62 exp: 05-2001) when washed using;
1. Distilled water only,
2. Distilled water for the metal parts and methanol for the filter and
3. Methanol only
(n =3 for each solvent combination errors are s.d.).
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Figure 5.17 Percentage drug recovered in the shells and cylinder o f  the incomplete SML 
tested at 60 1 min'1 using Ventolin (lot: M62 exp: 05-2001) when washed using;
1. Distilled water only
2. Distilled water for the metal parts and methanol for the filter
3. Methanol only
(n =3 for each solvent combination errors are s.d.).
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Figure 5.18 Percentage drug recovered in the incomplete SML tested at 60 1 min’1 using
Ventolin™ (n=3 for each solvent, errors are s.d.)
% Drug Recovered for stated 
Solvent
Stage 1.Water s.d. 2. Water/Methanol s.d. 3. Methanol s.d.
AM 10.8 0.0 11.4 0.2 14.8 0.9
TB 50.6 1.3 50.5 1.2 48.5 0.9
Shell 1 3.0 0.3 3.3 0.5 2.8 0.3
Shell 2 1.7 0.4 2.2 0.2 2.2 0.3
Shell 3 0.7 0.1 0.8 0.1 1.4 0.4
Cylinder 4.1 2.1 4.3 0.8 6.2 2.6
Filter 29.1 1.3 27.6 0.6 24.0 2.1
Discussion:
The filter was chosen as the experimental focus of this investigation as the model was 
manufactured from aluminium and the filter was glass fibre (the mouthpiece was made of 
silastic rubber but did not retain as high a percentage dose as the filter).
Using one way Analysis of Variance the stages displaying significantly different 
(specified significance level 0.05) % drug recovered data were:
AM: (P <0.001) the complexity of the actuator design probably retains a small amount of 
the drug. Methanol has a lower surface tension than water (22.6mN m*1 vs. 72.7mM m’1 
both at 20°C) so the solvent may be able to rinse around the obstacles in the actuator more 
effectively.
Shell 3: (P = 0.017) the % drug recovered from shell 3 was very small so the effect is less 
meaningful however, it may be due again to the lower surface tension of methanol and its 
ability to recover any drug deposited around the entrance or exit of a hole in shell 3.
Filter: (P = 0.015) when the filter was washed in methanol it appears that the recovered
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drug has decreased when in fact the case is that the total drug recovered from the model 
by weight increased so the % drug recovered from the filter is less than in the previous 
cases. It was decided that the cost of using methanol was too high to use the solvent 
routinely.
At this stage o f experimentation the SML was completed and so the following results are 
for the completed 5 Shell Model Lung. A brief report of experimentation comparing the 
use of an MDI alone and an MDI used with a spacer device (Volumatic™) may be found 
in Appendix B, Ms J Au-Yung performed the work (under personal direction at all times) 
for her B. Pharm. final year project
5.9 SML MDI Formulations comparisons
5.9.1 At 30 1 min'1
Using the SML MDI formulations of Ventolin™, Ventolin Evohaler ™ and Airomir ™ 
were assessed in the SML. The experiment was carried out as stated in section 5.4.2 and 
5.4.5. Comparisons were made to investigate the formulations’ performance in the SML 
under similar laboratory conditions.
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Figure 5.19 Percentage drug recovered for each formulation in the outer stages of the




















Figure 5.20 Percentage drug recovered for each formulation in the inner stages o f  the 
SML flow rate at 30 1 min'1 (n=3 in each case errors are s.d.)
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Figure 5.21 Percentage drug recovered in the SML tested at 30 1 min'1 using Ventolin™
Evohaler™ and Airomir™ (n=3 for each formulation, errors are s.d.)
% Drug Recovered
Ventolin Evohaler Airomir
Stage Mean s.d. Mean s.d. Mean s.d.
AM 14.7 0.0 21.0 0.3 30.0 0.6
TB 57.5 3.0 46.3 0.4 34.2 1.9
Shell 1 1.7 0.4 3.8 0.8 1.0 0.2
Shell 2 1.1 0.1 3.7 0.5 0.9 0.1
Shell 3 0.8 0.0 1.8 0.2 0.8 0.6
Shell 4 1.2 0.5 1.6 0.4 1.2 0.0
Shell 5 5.9 0.9 3.0 0.6 4.4 0.3
Bk Plate 0.6 0.0 1.8 0.0 0.5 0.2
Filter 16.4 4.7 17.0 1.7 27.2 3.0
Discussion:
Ventolin™ deposited over 70% of the recovered drug in the actuator, mouthpiece and 
throat regions. The percentage drug deposited in the shells (including back plate as this is 
considered to be part of the ‘inner structure’ even though the collected drug was low) was
11.3%. The filter collected 16.4% an improvement on the situation seen in the 
incomplete SML at 60 1 min'1. It is possible that the more compact nature of the model, 
the extra shells and most certainly the lower flow rate has affected the fluid dynamics 
through the device and so a difference should have been expected anyway.
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Evohaler™ also deposits 67% of its recovered drug in the actuator mouthpiece and throat 
region. The total drug collected in the shells (including the back plate) was 15.7% and 
17% of the recovered drug was found in the filter.
Airomir™ had the least recovered drug in the actuator, mouthpiece and throat regions at 
64.2%. The total drug collected in the shells (including back plate) was 8.8%. The 
percentage of drug recovered on the filter was 27.2%. The filter collection was very high 
and comparable to the filter deposition seen in the incomplete SML when tested at 
60 1 min'1.
The deposition profiles of all three formulations are very interesting. The general pattern 
of deposition seen in the shells for Ventolin™ and Airomir™ are quite similar. 
Evohaler™ however, appears to deposit more evenly throughout the shells. The rise in 
deposition over the five shells and the high deposition of drug in the filter for Airomir 
suggests that this formulation contains the finest particles of the three tested here.
5.9.2 At 60 1 min'1
Using the SML MDI formulations of Ventolin™, Ventolin Evohaler ™ and Airomir ™ 
were assessed in the SML. The experiment was carried out as stated in section 5.4.2 and 
5.4.5
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Figure 5.22 Percentage drug recovered for each formulation in the outer stages o f  the
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Figure 5.23 Percentage drug recovered for each formulation in the inner stages o f  the 
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Figure 5.24 Percentage drug recovered in the SML tested at 601 min'1 using Ventolin™
Evohaler™ and Airomir™ (n=3 for each formulation, errors are s.d.)
% Drug Recovered
Ventolin Evohaler Airomir
Stage Mean s.d. Mean s.d. Mean s.d.
AM 9.5 1.2 12.6 3.5 20.2 1.9
TB 67.9 2.1 65.4 8.6 53.1 0.4
Shell 1 4.2 0.7 5.3 2.6 4.5 1.5
Shell 2 2.5 0.4 4.3 2.0 2.9 0.8
Shell 3 0.6 0.0 1.4 0.7 1.6 1.0
Shell 4 0.6 0.3 0.8 0.2 1.5 1.0
Shell 5 1.5 1.1 2.7 2.3 2.7 0.9
Bk Plate 1.2 0.1 2.2 0.8 1.5 0.4
Filter 11.9 2.8 5.3 1.0 12.0 1.7
Discussion:
Ventolin™ drug deposition in the actuator, mouthpiece and throat regions was 77.4% of 
the recovered dose. The percentage drug recovered in the shells (including the back 
plate) was 10.6% a decrease at the higher flow rate. The drug recovered from the filter 
was 11.9% at 60 1 min'1 at 30 1 min'1 it was 16.4%.
The Evohaler™ percentage deposition in the actuator, mouthpiece and throat regions was 
78%. The deposition seen in the shells (including the back plate) was 16.7% a slight 
increase at the higher flow rate. The percentage drug recovered in the filter was only 
5.3%.
Airomir™ had a similar percentage drug recovery in the actuator, mouthpiece and throat
region as the other two formulations at 73.3%. The drug recovery in the shells (including
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the back plate) almost doubled at the higher flow rate to 14.7% (from 8.8%). The filter 
percentage drug recovery more than halved in value from 27.2% to 12% at 60 1 min'1.
The errors associated with the results here are in part due to the fact that as flow rate 
increases turbulent flow becomes more prominent and makes particle deposition less 
predictable. The errors used are the standard deviation which although should generally 
not be used for such a small sample, it gives an idea of the repeatability of the 
experimental procedure.
It can be seen that the profiles in the shells of the three formulations has altered, it 
appears that the pattern of deposition has shifted towards the inner shells (shell 1 and 2). 
The filter deposition has decreased and the deposition in the throat and bifurcation region 
has increased for each formulation.
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5.10 Andersen Cascade Impactor MDI Formulation comparisons
These experiments were performed to assess the difference between the formulations. It 
is possible as discussed to analyse the formulations using the ACI and gain valuable data 
about the formulation properties.
5.10.1 Ventolin™
Using the ACI MDI formulations o f  Ventolin™, Ventolin Evohaler ™  and Airomir ™  
were assessed. The experiment was carried out as stated in sections 5.5.2 and 5.5.3.
Figure 5.25. Percentage drug recovered for Ventolin™ in the inner stages o f  the ACI, 
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The data represents 6 sets o f  experiments all performed on one Ventolin™  formulation. 
Five shots were fired to waste and then ten shots were used during each experiment. 
Using a spreadsheet designed to give aerosol cloud data from an Andersen cascade 
impactor (courtesy o f  Dr. D A Lewis, Vectura Limited, University o f  Bath Campus, Bath, 
BA2 7AY). The following results were obtained.











The mean MMAD was found to be 2.8pm however, it can be seen that perhaps the 
MMAD found from shot numbers 36-45 is a little high. Excluding the high value gives 
a mean MMAD of 2.7pm(± 0.1). It was found that the FPF for Ventolin™ was 42.1pg 
(± 8.6).
T W
Product information for Ventolin (GlaxoWellcome Inc., March 2000) states the 
formulation contains a suspension of Salbutamol drug particles 95% <10pm. This study 
has found the mean value of the drug particles < 10pm was 43%. It is probable that the 
product information is quoting the initial size o f the Salbutamol particles put into the 
device. On exit from the device particles can agglomerate thus increasing the mean 
aerodynamic diameter.
Data presented by Lewis (Management Forum, 1998) is in good agreement with this 
study. The study found Ventolin™ to have an MMAD of 2.5pm (±0.1) (n=6) and FPF 
of 41.6pm (± 6).
The data collected appears to be similar to other studies performed on Ventolin™ and so 
it is viewed as reliable. The data presented suggests that Ventolin™ MDI to be a stable 
formulation giving reproducible results.
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5.10.2 Evohaler™
Figure 5.28 Percentage drug recovered for Evohaler™ in the inner stages of the ACI,
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The data represents 3 sets of experiments all performed on one Evohaler™ formulation. 
Five shots were fired to waste and then ten shots were used during each experiment. The 
following results were obtained.
Figure 5.30 ACI data describing the aerosol cloud.





The mean MMAD was found to be 4.3pm. This is higher than the MMAD found for 
Ventolin™ and is a possible explanation for the different behaviour of each formulation 
in the SML as seen in section 5.8. The FPF was found to be 38.3pm (±3.6).
Product literature states that 10 -  20% of the inhaled dose reaches the lower airways 
(http:/uk.gsk.com/products/assets/uk_Ventolin_Evohaler.pdf). Unfortunately Tower 
airway’ is not defined so we cannot make a relevant comparison with the manufacturers 
data.
The study carried out by Lewis (Management Forum, 1998) stated that Evohaler™ had 
an MMAD of 3.2pm (±0.2) and a FPF of 33pg (±3). The study presented here shows a 
higher MMAD than was found Lewis 1999, the FPF is in better agreement.
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5.10.3 Airomir™
Figure 5.31 Percentage drug recovered for Airomir™ in the inner stages of the ACI, flow
rate at 28.3 1 min'1 (n=6)
© 10
Figure 5.32 Complete Airomir™ ACI data (28.3 1 min'1, n=6)
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Five shots were fired to waste and then ten shots were used during each experiment. The
following results were obtained.










The mean MMAD was found to be 1.5pm, indicating a very fine aerosol cloud. The 
mean FPF was found to be 44.6pg (±12.7).
Airomir™ is a solution formulation; its valve is smaller than conventional CFC 
formulations (25pi). Product development data suggest it is a stable formulation 
(Tansey, 1995).
Estimating MMAD from product data (Leach, 1996) gives a higher result than the study 
here, 2.4pm. The product literature does suggest that the manufacturers are aware of 
some erratic dosing emissions from the can throughout its life. This however does not 
account for the very low MMAD results reported here. The errors were found to be large 
and further reproducibility problems were identified when the can was weighed after each 
actuation. Lewis found the MMAD of Airomir™ to be 2.6pm (±0.1) and the FPF 44pg 
(±4) (n=3).
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The study reported here does not estimate the M MAD o f  Airomir™ MDI to be similar to 
the studies performed previously. The analytical problems associated with Airomir are 
thought to be due to formulation issues it is possible that the particles will be dry when 
they enter the body o f  the impactor and bouncing o ff  the plates may contribute to the 
large errors seen. To reduce this factor it may be worth coating the plates o f  the impactor 
with a suitable component making them ‘sticky’ and so reducing the possibility o f  dry 
particle bounce and / or re-entrainment.
5.10.4 Bricanyl™
Figure 5.34 Percentage drug recovered for Bricanyl™ in the inner stages o f  the ACI, 








Figure 5.35 Complete Bricanyl™ ACI data (28.3 1 min'1, n=3).
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Five shots were fired to waste and then four shots were used during each experiment. 
The following results were obtained.
Figure 5.36 ACI data describing the aerosol cloud.





The mean MMAD for Bricanyl was found to be 3.0pm and mean GSD was 2.2.
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5.10.5 General discussion
Evohaler™ appears to be deposited more in the inner shells (shells 1 and 2) of the SML 
than Ventolin™. The Ventolin™ formulation having a lower MMAD and GSD contains 
fine particles in a smaller size range thus, reaching further into the SML and displaying 
more of a ‘peak’ at shell 5. The higher GSD of Evohaler™ indicates that the aerosol 
cloud contains fine particles in a wide size range i.e. more polydisperse, this may explain 
the deposition distribution in the SML being wider than for either Ventolin™ of 
Airomir™.
The GSD for Airomir™ was variable and in general the errors associated with this 
formulation are greater than with Ventolin™ or Evohaler™. The small MMAD explains 
the higher drug recovery of this formulation in the filter of the SML at 301 min'1.
The Bricanyl™ MDI studied had a similar GSD to the Evohaler™ formulation however, 
the MMAD was found to be 3.0pm, slightly higher than that seen for Ventolin™.
5.11 SML Bifurcation re-manufacture
Details of the reasons for changing the manufactured component are outlined in section 
2.3.10. The SML for routine experimentation was run at 30 1 min'1 this is an equivalent 
value to the flow rate used in the ACI (28.3 1 min'1). The experiment was carried out as 
stated in sections 5.4.2 and 5.4.5. The flow rate used was 30 1 min'1 and the formulations 
were Ventolin™ Bricanyl™ MDI. Figures 5.37 and 5.38 show the old bifurcation in the 
first instance and the new bifurcation in the last.
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Figure 5.37 Percentage drug recovered in each o f  the outer stages o f  the SML using 
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Figure 5.38 Percentage drug recovered in the shells o f  the SML using either the new or 
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Figure 5.39 Percentage drug recovered in the SML tested at 301 min"1 using either the
New or Old Bifurcation in position. Ventolin™ and Bricanyl™ were the MDI
formulations used (n=3 for each data set, errors are s.d.).
% Drug Recovered
Ventolin™ Ventolin™ Bricanyl™ Bricanyl™ .
New Bifurcation Oid Bifurcation New Bifurcation Old Bifurcation
Stage Mean s.d. Mean s.d. Mean s.d. Mean s.d.
AM 17.1 0.6 14.7 0.5 13.4 1.0 12.9 0.2
TB 56.7 1.0 57.5 3.4 63.7 1.9 69.1 2.6
Shell 1 5.2 0.3 1.7 0.3 7.8 1.7 5.5 0.6
Shell 2 3.1 0.3 1.1 0.3 5.9 0.5 4.4 0.7
Shell 3 0.8 0.2 0.8 0.4 1.2 0.1 0.8 0.4
Shell 4 0.8 0.2 1.2 0.5 0.6 0.2 0.7 0.3
Shell 5 2.8 1.6 5.9 1.1 1.2 0.6 1.7 0.9
Bk Plate 1.5 0.2 0.6 0.1 1.7 0.7 1.5 0.6
Filter 11.9 0.8 16.4 4.7 4.6 1.7 3.4 1.3
Discussion:
Data was analysed using one way Analysis of Variance (Minitab).
Ventolin™:
The new bifurcation affected deposition of drug in the actuator and mouthpiece 
(P<0.001). Throat and bifurcation deposition was not affected significantly. It is clear 
from figure 4.38 that the entire deposition pattern seen in the shells is affected, the ‘peak’ 
of deposition has moved towards the inner shells (shells 1 and 2) when the new 
bifurcation was used. P< 0.001 for shell 1 and P= 0.001 for shell 2. Shells 3 and 4 
display no significant change in the % drug recovered value. This may be due to the fact 
that very little drug is deposited in these shells anyway. Deposition in shell 5 decreased 
(P= 0.051) with the new bifurcation however; more drug was deposited in the shells as a
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whole and less in the filter. The total % drug deposition in the shells (including the back 
plate) was 11.4% with the old bifurcation; the new bifurcation improves the situation to 
14.3% (P< 0.050).
Bricanyl™:
The new bifurcation does not significantly affect deposition in the actuator and 
mouthpiece as seen in Ventolin™. Throat and bifurcation deposition was significantly 
increased with the new bifurcation in place (P< 0.050). Shell 1 (P=0.084) was increased 
but not greatly deposition in shell 2 was significantly increased (P<0.050). The slight 
changes seen in other parts of the model are not significant changes but are observed and 
noted. Total shell drug recovery increased from 14.5% to 18.4% a significant increase 
(P <  0.050).
Patient data as reported by Borgstrom and Newman, (1993) is a little lower than the value 
for total lung deposition seen in SML data (with new bifurcation fitted). It was reported 
that at a mean flow rate of 33.8 1 min'1 is 8 subjects a mean total lung deposition of 
16.7% was recorded.
The nature of aerosol testing involves many errors the alteration of the bifurcation was 
deemed a success and was used routinely from this point onwards as part of the SML.
5.12 Dry Powder Inhaler Studies
DPI’s are devices delivering a formulation of drug with an excipient such as lactose 
which acts as carrier for the drug particles. The devices deliver a unit dose of the drug.
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The formulation may be stored in various ways, for example in a blister, capsule or unit 
fill device. The devices are generally well used by patients because they are automatically 
actuated the contents are delivered as the patient inhales. Problems with DPI’s include 
irritation of the patients’ throat by the powder, inability of the patients’ inhalation force to 
partly or fully remove the whole dose and settling out of the powder and drug within the 
device or packaging unit. Even though the model was designed for use with metered 
dose inhalers it is preferable for any device to be used for all pharmaceutical aerosol 
devices.
The model was coated with a 10% v/v solution of glycerol in methanol to provide a ‘wet’ 
surface for the dry powder to deposit thus reducing the possibility of the particles 
bouncing off a dry surface. For the purpose of comparison the DPI formulations used 
were analysed using an ACI, the plates were coated as above. The ACI was run at 28.3 1 
min*1 it is appreciated that this flow rate is not suitable for testing DPIs but for the 
purposes of comparison it was deemed necessary and suitable. The formulations used 
were Bricanyl™ Turbuhaler and Ventolin™ Diskhaler. The purpose of these 
experiments was not to make a direct comparison of the formulations and devices but to 
assess the qualities of the SML when using DPIs. The experiments were carried out as 
described in section 5.4.2 and 5.4.5.
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5.12.1 SML / ACI Bricanyl™ Turbuhaler™
The results for Bricanyl™ Turbuhaler™ do not include data for actuator retention of drug 
because the formulation is a self contained system that cannot be dismantled. The first 
component to be washed was therefore the mouthpiece (M).
Figure 5.40 Percentage drug recovered for Bricanyl™ Turbuhaler™ in the outer stages 
of the SML flow rate 30 1 min'1 (n=6 errors are s.d.)
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Figure 5.41 Percentage drug recovered for Bricanyl™ Turbuhaler™ in the inner
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Figure 5.42 Percentage drug recovered for Bricanyl™ Turbuhaler™ in the ACI, 
flow rate at 28.3 1 min'1 (n=5)
The data represents 5 sets of experiments all performed on one Bricanyl™ Turbuhaler™ 
formulation. Two shots were used during each experiment. The following results were 
obtained.










The MMAD for the formulation was 5.1pm according to this comparative study. The 
aerosol cloud produced by the Turbuhaler appears to be of a good quality as the mean 
GSD was found to be 2.1. The distribution of the drug in the SML indicates that the 
MMAD will be higher than that seen in MDIs. The total shell recovery for the 
formulation was 22.1%. Generally the SML gives a good representation of the 
formulations characteristics.
Radiolabelled Terbutaline delivered via Turbuhaler™ was found to deposit in the lungs 
of 8 subjects at a mean value of 21.4%. This value was found to fit well with similar 
studies performed using gamma scintigraphy (Borgstrom and Newman, 1993). The study 
was performed using two-dimensional imaging but for total lung content provides a 
useful source of data and is in good agreement with SML data. The flow rates used were 
different, patient mean data for inhalation follow rate was calculated to be 57.8 1 min*1.
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Data from a study on radiolabelled Terbutaline administered to patients via a 
Turbuhaler® (Conway et al, 2000) compares favourably with this experimental data.
The study used a peak inhalation rate of 62 1 min'1, this experiment was performed under 
flow conditions of 30 1 min’1 it is therefore expected that lung deposition in the Conway 
study will be higher than that reported here. When adjusting for no actuator recovery, the 
data from Conway’s study was gathered non-destructively, the comparison is detailed in 
figure 5.44. The specific data of deposition per shell does not compare well with the 
SML however the problems with the novel device will be addressed in Chapter 6.
A pharmacokinetic method of ascertaining Terbutaline deposition and effect in asthmatic 
patients was reported by Borgstrom et al., (2000). Peak inhalation rate was not stated 
however it is understood that the mean forced expiratory volume was 85% of normal. 
Mean Lung deposition when using a Turbuhaler 0.25mg dose of Terbutaline is reported 
in figure 5.44 Both patient studies used here cannot be directly compared with the SML 
as the methods of collecting the data are different, the dosing regimes cannot be 
replicated and in the Conway study a Turbuhaler 0.5mg device was used.
Generally the SML gives a good representation of the formulation characteristics. It can 
be seen that the SML is at least collecting particles in similar quantities as real patient 
data suggest.
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Figure 5.44 Comparative data for Terbutaline delivered via a Turbuhaler® device, y 
indicates the Conway study, Pk indicates the Borgstrom study and SML indicates the 
study above.
% Deposition
Stage Y Pk SML
Mouthpiece and Throat regions 62 76.8
Lung / Shells 37.5 20.8 23.2
When the Borgstrom study looked at lung deposition with a 0.5mg terbutaline dose it was 
found that the percentage deposition decreased to 16.9%. Possibly at the higher dose 
more drug clearance occurred in the lung so less drug was detected.
5.12.2 SML / ACI Ventolin™ Diskhaler™
Figure 5.45 Percentage drug recovered for Ventolin™ Diskhaler™ in the outer stages of 





Figure 5.46 Percentage drug recovered for Ventolin™ Diskhaler™ in the inner stages of
the SML flow rate 30 1 min"1 (n=5 errors are s.d.)
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Figure 5.47 Percentage drug recovered for Ventolin™  Diskhaler™ in the ACI, flow rate 
at 28.3 1 min"1 (n=5)
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The data represents 5 sets of experiments all performed on the Ventolin™ Diskhaler™ 
formulation. Five actuations were used during each experiment. The following results 
were obtained.










The MMAD as found in this comparative study was 4.7pm and the mean GSD was 3.0. 
The aerosol cloud is finer but more polydisperse than in the previous example. This may 
explain the more even spread of distribution between the shells. It was likely in both 
cases that the errors associated with this experimentation were heavily influencing the 
outcome. The total shell recovery (including the back plate) for the Ventolin™ 
Diskhaler™ was found to be 16.2%. A particular problem encountered with this 
formulation appears to be the amount of drug retained in the actuator. From a patient 
perspective if this region isn’t cleaned on a regular basis drug delivery may be reduced as 
deposits of the formulation build up.
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5.13 Ventolin MDI performance at various flow rates
An investigation was undertaken to assess the effects o f  flow rate on the model with the 
new bifurcation in position. A Ventolin™ MDI was used at flow rates o f  10, 30 and 
55 1 min'1, the maximum flow rate achievable. The external filter impeded the flow rate 
so 60 1 min'1 as previously achieved in the incomplete SML could not be reached.
Figure 5.49 Percentage drug recovered for each outer Stage o f  the SML at 
10 1 min'1, 30 1 min'1 and 55 1 min'1 (n=3 and errors are s.d.)
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Figure 5.50 Percentage drug recovered for each inner Stage of the SML at
10 1 min'1, 30 1 m in'1 and 55 1 min'1 (n=3 and errors are s.d.)
10 - 10 I min' 
30 I min' 
55 I min'
Shell 5 Bk PlateShell 3 Shell 4Shell 2Shell 1
Stage






s.d. 30 I min'1 s.d.
Mean at 
55 I min'1 s.d.
AM 15.2 0.8 14.8 0.1 13.5 1.8
TB 57.3 4.2 66.4 0.8 55.4 3.8
Shell 1 3.8 1.8 6.6 0.9 9.3 1.9
Shell 2 2.1 0.8 3.3 0.6 4.3 0.5
Shell 3 0.6 0.2 0.9 0.0 0.9 0.1
Shell 4 0.6 0.1 0.6 0.1 0.5 0.2
Shell 5 0.5 0.1 0.7 0.2 0.6 0.2
Bk Plate 1.0 0.3 1.6 0.3 1.8 0.4
Filter 19.0 2.1 5.1 1.1 13.8 0.6
168
Discussion:
Although we can theoretically attribute cut points to shell 1 at these flow rates. The fluid 
dynamics throughout the model significantly alters deposition throughout. The pattern of 
deposition cannot be predicted as the model does not behave as an impactor and we have 
evidence for impaction only in shell 1 at 301 min'1. Total shell deposition (including 
back plate deposition) increases from 8.6% at 10 1 min'1 to 13.7% at 30 1 min'1 to 17.4% 
at 55 1 min'1. Filter deposition is a point of interest in that it decreases form 19% at 10 1 
min'1 to 5.1% at 30 1 min'1 and then increases to 13.8% at 55 1 min'1. Section 5.10 
(bifurcation remanufacture) shows a filter deposition of 11.6% at 30 1 min'1 so this is in 
part experimental error. The general trend of the deposition pattern does seem to shift 
towards the inner shells (shells 1 and 2) as previously seen in the incomplete SML 
section 5.7.
5.14 General Discussion
It is drawn to the attention of the reader that the SML losses in some cases are up to 20% 
of the drug administered. It is thought this occurs due to the small area of filter available 
for particle collection and therefore the airflow through it was high resulting in possible 
losses through the filter. It was seen during experimental work that the filter if not 
adequately supported by a mesh would break. Suggestions for further improvement of 
the filter mechanism and model performance in general follow in section 6.6.4.
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Chapter 6 Conclusion and Further Work
A novel aerosol testing device, the Shell Model Lung, has been designed, manufactured, 
calibrated and investigated. The device demonstrates that in vitro devices could be made 
more realistic. The SML at this stage provides a good starting point for further 
development of a model collecting particles by deposition methods other than impaction 
as occurs in the human lung.
6.1 Calibration of the SML
Calculated predicted cut-points at shell 1 are in fairly good agreement with calibration 
data. The results show that shell 1 collects aerosol particles by impaction at 301 m in1. It 
was not intended that each stage o f the model should collect particles by impaction as 
outlined in section 1.9. The model appears to be collecting particles less than 10pm in 
the shells and filter this should be lower and proposed methods of improving the 
performance of the model are suggested below.
During calibration of the model only Shell 1 demonstrated a collection efficiency curve 
passing through the 50% point. The curve is steep and therefore it can be said that this 
shell collects particles by impaction. Focusing on the initial aims of this project this point 
seems irrelevant for the remaining shells as impaction is not the main method of particle 
deposition further into the human lung. A cut-point of 7.2pm at shell 1 means that it is 
likely any aerosol particles reaching past that point would be less than 10pm. A
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theoretical cut point of 5.4pm at 60 1 min'1 would be suitable for the work if the errors 
involved at the higher flow rate could be reduced. Data supports the use of the SML over 
10 to 601 min'1. The 2DSML has been investigated over 10 to 95 1 min'1 (see section 
3.7). Due to economic constraints the SML was only calibrated at 301 min'1, the most 
relevant for the purposes required here.
6.2 Success and additional requirements
It has been demonstrated that the SML collects particles by impaction and other 
mechanisms. The SML was designed to collect particles by various methods as occurs in 
the respiratory tract. Flow regimes in the lung are such that it is expected that particles 
will impact in generations 1 to 4. As further branching occurs, moving through the 
generations, the flow velocity decreases and particle deposition is more dependent upon 
gravitational settling and diffusion. The model is robust and not complicated to operate. 
The run times are comparable to using an ACI in the laboratory. Other devices such as 
the TSI have much shorter run times but the data collected is rather limited.
Results from the flow visualisation experiments (section 3.9.3) demonstrate that even at 
low flow rates streak lines introduced into the flow hit the back of the throat. It is 
reasonable to assume a MDI aerosol cloud will at a sampling flow rate of 301 min'1 in air 
(2 1 min'1 in water) will cause further turbulence in the initial throat section and at the 90° 
bend.
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The flow visualisation of a cloud in shell 1 and 2 demonstrates how an aerosol ‘bolus’ 
would disperse (figure 3.20). It appears that the top comer in particular allows 
recirculation of the cloud. The angle of the bifurcation and the direction of the flow 
dictate the direction the cloud exits the bifurcation. The void spaces and resulting 
recirculation allow greater mixing of the particles making deposition more likely.
Results shown in figure 5.44 demonstrate that the SML collects particles in a comparable 
ratio to those seen in y - scintigraphy and pharmacokinetic studies. Although the SML 
results are not ‘matching’ the patient data seen here it is envisaged that the model could 
with slight modifications become a comparable analytical tool.
The SML contains five shells a suitable number of collection stages, it is possible that a 
pre-filter could be incorporated however as the model was designed to be more realistic it 
is unlikely this would be of any benefit. A USP throat was used as the entry port in all 
the experimental work reported here and a suitable filter was used at all times.
Recovery of drug from the SML was variable and the initial incomplete model gave 
fewer errors during analysis. Reasons and suggestions for improving this will be 
discussed below. Generally the errors seen could be said to result from the fact that 
collection mechanisms in the model were not as defined as in other particle collection 
devices. This is unfortunately inherent in the model although if some of the further 
design ideas were to be incorporated as described below the situation may be improved.
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It was thought when using the more volatile formulations the errors involved could be 
attributed to particle bounce. Coating the SML during the DPI studies proved an 
effective way of minimising errors so this may also be suitable when using ‘drier’ MDI 
formulations.
The model could be acceptable for quality control purposes depending upon reliable 
validation of the model. This would have to include work incorporating y scintigraphy to 
demonstrate the application of the model to real data. It may not be as applicable to in- 
process quality assurance procedures involving for example stage removal for quick 
particle size checking. The SML was designed as a ‘flow-through’ device it is probable 
that the nature of the fluid dynamics would alter significantly on removal of a shell or 
shells. This was not investigated although may provide scope for further work on both 
the 3D and 2D models.
6.3 Effects of model re-design
It was observed that during the initial experiments on the ‘incomplete’ SML a generally 
higher recovered dose was collected than when the 5 Shell model was used. It was 
thought that the airflow effects contributed to the loss of particles through the filter (see 
section 6.6.4 below).
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Re-manufacturing the bifurcation has improved the collection performance of the Shells. 
It would have been interesting to calibrate the model using every combination of model 
component.
6.4 Properties of commercial inhalers
Throughout this work it has been evident that commercial MDFs and DPI’s are rather 
variable in their performance. Even when using standard methods and applying 
controlled conditions it was often the case that experimental errors involved were so large 
that many results were disregarded. Looking at data presented here and from other 
sources as seen in chapter 5 it is clear that experiments involving aerosols should always 
be performed under controlled conditions using designated equipment to be sure that 
comparisons can be drawn.
As dosing devices inhalers are commercially successful as they are, in most cases, more 
acceptable to the patient, reducing systemic delivery of drugs and therefore unwanted 
side effects. The reliable analysis of the systems proves difficult in that patient 
variability (physiologically) is large, patients use of the devices correctly has to be taught 
by a healthcare professional and the drug delivery device has moving parts, seals and is 
made of materials which may confer an electrostatic charge on the particles.
Formulations contained in such devices vary considerably offering the patient changes in 
appearance of the packaging, ‘feel’ of dosing when actuating related to the valve volume 
and taste.
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6.5 Comparison of 2DSML data with 3DSML findings of 
deposition affected by flow rate
Further investigation into the similarities between the 2DSML and the 3D model is 
required however, it is evident that changes in static pressure over the 2DSML as the 
flow rate increases (section 3.7) means that flow rate in the 3DSML has an effect on 
particle deposition. CFD would be of benefit here to calculate the changes in airflow 
through the model and following on from that give predictions of particle deposition 
patterns.
6.6 Further design proposals for improving the performance of 
the model
The following sections describe work the author would suggest for future investigation of 
the SML.
6.6.1 General design / manufacturing improvements
It is thought the basic structure of the model is sound and although improvements of 
performance will be suggested further design will be discussed here.
Throughout the use of the model it has been found to wear in critical areas. The majority 
of the fittings are made using screws. As the model is made of aluminium the screws 
used have worn threads in the screw holes. A particular problem was encountered in the 
bifurcation to back plate fitting. The screws had worn the aluminium back plate so much
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that a close fit could no longer be achieved. New holes were drilled into the two 
components and new larger threaded screws were supplied by the Department of 
Pharmacy workshop.
The design of the model would have to be reassessed in the light of these in-progress 
findings. This problem may be overcome by introducing a method of pushing the fittings 
into the back plate instead of using the present method. Design suggestions include:
• Incorporating a clip mechanism. Once each shell was positioned correctly a clip 
secured to the back plate would fit firmly over the holding edge of the shell.
• Introducing a ‘stack and hold’ feature of the shells. The shell could be push-fitted 
into the back plate ensuring a tight seal.
It has been suggested that for routine testing a simplified method should be acceptable 
(Van Oort and Truman, 1998). If the model was quick to use and analyse time wouldn’t 
be taken up by routine laboratory procedures and data collection could be more complete.
6.6.2 Design of a new final shell and enclosing case
The original design for the 5th shell could be manufactured with the intended number of 
holes (figure 2.5) this would of course increase the cost of the model but, for research 
purposes it is thought this would be a suitable investment.
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When the incomplete SML was used it was clear that in comparison deposition in shells 2 
and 3 was higher than when shells 4 and 5 were added to complete the model. The 
reason for this is believed to be the position and size of the outlet pipe. When the outlet 
was connected to the cylinder it was further away from the shells and the increasing air 
velocity associated with it did not interfere with the fluid dynamics of the air passing 
through shells 1, 2 and 3. For this reason the fifth shell would be encased in a final 
collection vessel similar to the cylinder design of the incomplete SML as described in 
section 2.3.9.
It would be interesting to design into the model a feature allowing it to be more closely 
correlated to the human lung. This would reduce the analytical practicality of the model 
but may give an insight into its potential for modelling lung efficiency more closely 
rather than aerosol deposition. The proposed design would consist of a packing material 
similar to a sponge or other porous material. The material could be soft or rigid 
depending on the use required. If breathing patterns were to be investigated then foam 
could be used. Each shell could house material o f a specific pore diameter or the whole 
model could be reconstructed using graduated pore sized material.
6.6.3 Introduction of an anatomical throat
The effect of inlet dimensions on the collection properties of aerosol testing devices 
influences deposition in the device itself (Fults et al, 1991). The shape and size of the 
inlet will have an effect on the evaporation of the droplets, turbulence and therefore 
inertial deposition (impaction).
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A possibility for improving the correlation between in vitro and in vivo models may be to 
attach a biological throat (Velasquez and Gabrio, 1998) to the model. A USP throat 
collected approximately 80% less of drug per dose than a ‘biological’ replica throat 
(Gabrio B.J. et a l, 1999). An ‘anatomical throat replica’ developed by Astra Draco 
(Olsson B., et al., 1996) retained 50 to 80% of the dose delivered via a dry powder 
inhaler compared with 10 to 20% using a glass bulb (TSI) throat.
Adding a oral throat cast (Srichana et a l, 1999) reportedly reduced the cut point in a TSI 
from 6.3 pm to 5.2pm. When using an MDI 42% of the delivered dose was retained by 
the glass bulb throat whereas the anatomical throat collected 77% of the dose. It can be 
said that an anatomical throat affects the amount of drug collected further in the device.
It was demonstrated that even when using the ‘anatomical throat replica’ in vitro results 
of fine particle fraction were almost 50% more than in vivo lung deposition data 
(collected using the charcoal block method).
It is thought that the geometry of the throat replicas introduces more turbulence into the 
system. The casts were made after studying MRI scans of human throats. Throat 
geometry changes when an actuator is held in the mouth and the tongue is pushed back 
towards the throat (Fan and Cheng, 2000), the constriction that is produced may account 
for the over prediction in potentially respirable particles. However the introduction of 
anatomically correct throat models is though to be crucial to the correct modelling of 
aerosol deposition in the lung (Van Oort and Truman, 1998).
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6.6.4 Flow Issues
There are problems with stage losses at the filter in the SML. This could be overcome if 
the area of the flow was increased. If the flow used was very high then the filter actually 
broke on a number of occasions allowing particles to escape. If the proposals made 
above (packing material included) were put into practice then it is likely that all the 
particles would be captured within the model. Another problem with the position of the 
outlet in shell 5 is that it is probably causing an increase in velocity that encroaches shell 
4 thus not allowing particle deposition by sedimentation. It has been shown that particles 
are likely to deposit in the lower regions of each shell (figure 3.20) and this is the area we 
are concerned with.
A simple modification to shell 5 could improve the drug loss through the filter. It is 
thought that airflow over a larger surface area would reduce the effect seen as described 
above. A diagram of a proposed redesign of shell 5 is shown in figure 6.1 below. The 
filter would be placed on a mesh support to provide a continuity of geometry. If the filter 
collects all the particles under 4.2pm as calibration data suggests are collected here we 
could draw more conclusions about the inhalers studied such as potentially classifying 
filter collection as the fine particle fraction of the aerosol cloud.
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The diagram is not to scale however if the filter diameter were 100mm in diameter this 
would provide a larger surface area for particle collection than is used presently and the 
velocity of the airflow through the filter would be greatly reduced.
An interesting experiment could be performed by introducing air into the model at the 
throat position instead of using a vacuum pump at the exit. Using the modified outlet as 
described above and introducing a modified Andersen (USP) throat (Figure 6.2) a flow 
could be introduced at the entry port allowing an even more marked reduction in velocity 
through the model.
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Figure 6.2 Schematic diagram of the proposed Modified Andersen (USP) throat 
a. Side view (diagram not to scale)
^  Inhaler Device
Air Inlet
Modified USP throat
b. End view (diagram not to scale)




Airflow could be pumped into the model at an appropriate flow rate and timed 
accordingly. It may also be possible to introduce humidified air to model the humidity in 
the human lung. The characteristics of the aerosol particles could then be investigated 
under such conditions. It has been demonstrated that for nebulisers humidity has a 
significant effect on the size of the droplets produced (Finlay et a l, 1997). It would be 
beneficial to the study of this device to incorporate a system of humidification to 
investigate hygroscopic growth of particles. Airborne particles in particular are subject to 
growth under humid conditions (Hitzenberger et al, 1997) for the SML to have uses 
outside the pharmaceutical field in aerosol research it would be of benefit to include such 
mechanisms for potential use in environmental science.
It would have been useful to be able to use a breathing device during these studies. Using 
a realistic breathing pattern for the investigation of aerosols would have suitably 
enhanced the characteristics of the SML as an in vitro device. A piston set-up as used in 
the Electronic lung™ could have been employed (Brindley et al, 1994). It has been 
suggested for the analysis of nebulised aerosols (Dennis, 1998) in particular this would be 
of value as the patient inhales the aerosol throughout a period of time rather than a simple 
actuation. Nebulisers are devices intended for use over a period of time for patients who 
find it difficult or impossible to use other methods of drug delivery to the lung. They 
supply a constant stream of medication to the patient. The aerosol produced by a 
nebuliser contains water vapour. As the water evaporates the temperature of the aerosol 
can fall to around 10°C in a few minutes (Dennis, 1998). There are two types
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commercially available, air blast and ultrasonic nebulisers. A new type of nebuliser is 
under investigation (Stangl et al, 2000). The ‘vibrating membrane nebuliser’ aims to 
reduce the drug loss seen within the walls and filtering mechanisms of traditional 
nebulisers. Although they are not as widely used as MDIs or DPIs they are very effective 
in treating patients with chronically diseased airways.
6.6.5 Coating
It may be advantageous to coat the throat surface of the shells even when using MDIs. 
Coating impaction surfaces improves particle deposition when one actuation of an MDI 
was presented to an impactor (Ross et al, 1996) but the case was reversed when up to 10 
actuations were used. Coating plates and collection cups o f and ACI and MMI has been 
shown to be beneficial when using single actuations (Nasr et a l, 1997). As the surfaces 
of the larger shells provide a larger deposition area than a regular impactor it may be 
advantageous to investigate this further. Routine coating o f the inlet is advisable when 
using DPIs (Van Oort and Truman, 1998) therefore for comparative purposes it is 
probably wise to use the same techniques for MDIs.
Coating a USP throat was shown to increase throat deposition by over 50% when using 
an MDI (Shrubb, 1998). It is thought that particularly when using MDIs that produce 
drier particles coating the throat would be advantageous in reducing errors associated 
with particle bounce.
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Modifying the coating of a material to imitate the lung during a period of hypersecretion 
as occurs during an asthma attack would be an advantage (Pattern, 2000). The immune 
system reacts intensely during an asthmatic episode so it would help investigators to 
observe the fact.
6.6.6 Evidence based redesign
The general SML design has proved to be valuable and has given a useful analytical tool. 
The model does not provide a direct correlation between in vitro and in vivo data. It is 
therefore necessary to improve the model to an acceptable level. It is unfortunately 
beyond the time and economic scale of this research project to investigate the 
possibilities of CFD based redesign. The use of CFD during this project has helped the 
understanding of fluid flow in the 2DSML and provided possible explanations for the 
high regions of deposition. The problems associated with turbulance and three- 
dimensional manufacturing techniques have been highlighted.
The best feature of CFD has not been exploited during the work presented here. A CFD 
mesh may when previously set up be modified and altered as necessary. This technique 
could be used to investigate the effects of altering the size and number of holes in each 
shell. The computations involved in gathering data are complicated and take many hours 
or even days in some cases. The CFD time available to this project was unfortunately not 
sufficient to perform these alterations.
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If the data could have been produced it would have been interesting to look at the 
redesign of each shell in turn and investigate the deposition properties associated with the 
cases described in figure 6.3. It is anticipated that this would involve in one instance 
halving the number of holes present in each shell and in another halve the airway 
diameter. It would be of interest to also rearrange the holes in the shell made possible 
using this advanced computational technique.
Figure 6.3 Table of hypothetical CFD data inputs for evidence based redesign.
Shell Mean Hole Diameter / mm Number of Holes (N)
Shell 1 5.43 3
Shell 2 3.02 21
Shell 3 1.82 149
Shell 4 0.99 1239
Shell 1 2.7 7
Shell 2 1.5 43
Shell 3 0.9 298
Shell 4 0.5 2478
Another possibility would then be to introduce a ‘breathing’ pattern into the CFD model 
to investigate the flow throughout an inhalation and exhalation phase.
Testing and experimentally determining the flow pattern through the model using a 
‘breathing’ pattern would be easier using the 2DSML. Analytical and experimental work 
as described in sections 3.5 and 3.6 would be possible.
Modelling generations of the airways deep in the lung is important when considering the 
delivery of drugs for systemic purposes or particles posing a hazard to health. Unlike the 
upper respirator tract acinar airways are in a constant rhythmic motion. This enables 
convective mixing of air in the alveoli necessary of course for respiration to occur. Wall
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expansions can therefore result in recirculation effects if the expansion is large enough 
and the airflow low enough (Tsuda et al., 1996). It was suggested that the acinar model 
based on theoretical and experimental data as supported by complex finding in rabbit 
lung excision and experimentation was valid.
The rhythmic alveolar model was physically investigated using a large scale silicone 
copy (Tippe and Tsuda, 1999). The alveolar flow was found to be largely dependent 
upon volume changes and low flow rates as had been suggested (Tsuda et al., 1996). 
Low Reynolds numbers do not therefore indicate in such complex geometric situations 
that the flow is simple and laminar.
6.6.7 Suggestions to create a larger deposition surface
Creating a larger surface area for particles to deposit would improve collection 
throughout the model. Between the shells ‘packing’ material could be included. It is 
thought glass beads of varying diameters could be introduced to create a filtering 
mechanism through the device with large beads in shell 1 and smaller beads between 
shell 4 and 5. A similar effect could be achieved with foam cut appropriately to fit 
between the shells this would have the advantage over glass beads by being one defined 
piece of material creating a packing surface that would not change with each use. Glass 
beads would have the same amount of space between them but would create 
geometrically diverse patterns (representing the airways) on each packing.
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6.6.8 Gamma Scintigraphy Studies
It is thought that it would be possible to image radionuclide in the SML. SPECT imaging 
provides spatial data and although this cannot be used to validate lung models (Fleming 
et al, 1996) it should be possible to make some correlation with the SML. The internal 
structure of the SML is very similar to the hemispherical model used for data 
interpretation therefore instead of trying to relate data per generation of a lung model it 
should be possible to directly see any similarities.
6.6.9 2DSML for aerosol testing
If the casing of the 2DSML was changed to aluminium it is likely that to assess the 
accuracy of the 2DSML analytical and experimental model it could be used for aerosol 
testing and undergo calibration testing. Using aluminium as the casing would prevent 
any undesirable electrostatic effects interfering with results. The model may after 
modification be more suitable for testing small doses than the three-dimensional model as 
there would be less surface area to wash and results may be more accurate.
6.9 Final Summary
It has been demonstrated that the SML collects particles by impaction and other 
mechanisms. The model does not replicate the impactors or impingers currently on the 
market. Further investigation and modifications should allow the model to be used for an 
in vitro respiratory model. The use of the SML in conjunction with the available testing 
methods would allow greater flexibility in the laboratory qualification of new 
formulations and active compounds.
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Appendix A - Percentage Drug recovery for sections 5.8 
to 5.13 inclusive
Data referring to: 5.7.1 Airomir™ at 301 min"1
Can / ex periment number
Stage 3.1 3.2 3.3 3.4 3.5 4.3 4.4 4.5 4.6 Mean St Dev
AM 29.44 26.60 24.46 25.05 24.97 26.60 24.46 25.05 24.97 25.73 1.61
TB 56.36 43.43 43.68 48.93 46.05 43.43 43.68 48.93 46.05 46.73 4.24
Shell 1 2.90 1.46 1.51 1.75 1.77 1.46 1.51 1.75 1.77 1.77 0.45
Shell 2 2.23 1.24 1.40 1.35 1.59 1.24 1.40 1.35 1.59 1.49 0.31
Shell 3 1.33 0.72 0.69 0.66 0.72 0.72 0.69 0.66 0.72 0.77 0.21
Cylinder 5.36 5.97 3.36 3.26 3.15 5.97 3.36 3.26 3.15 4.10 1.27
Filter 2.37 20.57 24.89 18.99 21.75 20.57 24.89 18.99 21.75 19.42 6.75
Data referring to 5.7.2 Airomir™ at 60 1 min'1
Can / experiment number
Stage 4.1 4.2 4.7 5.1 5.2 5.3 Mean St Dev
AM 18.91 19.96 18.59 18.99 17.96 17.84 18.71 0.77
TB 34.48 35.43 31.41 40.38 34.53 34.68 35.15 2.91
Shell 1 3.48 3.26 3.84 7.93 6.80 6.64 5.32 2.03
Shell 2 2.24 2.18 2.07 4.79 4.07 3.84 3.20 1.18
Shell 3 1.28 1.29 0.87 0.94 0.85 0.67 0.98 0.25
Cylinder 9.87 7.94 9.48 3.71 3.76 3.37 6.36 3.07
Filter 29.75 29.94 33.75 23.27 32.03 32.96 30.28 3.79
Data referring to: 5.7.3 Ventolin™ at 60 1 min*1
Can / experiment number
Stage 1.1 1.2 1.3 1.4 Mean St.Dev.
AM 10.87 12.26 13.78 12.29 12.30 1.19
TB 54.02 49.73 52.10 46.51 50.59 3.24
Shell 1 3.67 2.58 2.98 4.34 3.39 0.78
Shell 2 2.09 1.66 1.71 2.61 2.02 0.44
Shell 3 0.61 0.53 0.51 0.79 0.61 0.13
Cylinder 2.96 2.02 2.54 2.78 2.58 0.41
Filter 25.78 31.23 26.38 30.67 28.52 2.83
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Data referring to: 5.7.4 Suitability of solvents using Water, Water for the metal parts of 
the model and methanol for the filter (W/M) and Methanol for all parts.
Experimental conditions
Stage Water W/M Methanol Water W/M Methanol Water W/M Methanol Mean total St.Dev.total
A+MP 10.80 11.53 15.61 10.83 11.48 13.78 10.78 11.13 15.01 12.33 1.93
T+BIF 49.95 49.21 48.26 49.77 50.62 49.51 52.17 51.53 47.78 49.87 1.42
Shell 1 2.64 3.84 2.93 3.03 3.04 2.47 3.29 3.07 3.03 3.04 0.39
Shell 2 1.95 2.37 2.44 1.27 2.11 1.96 1.96 2.09 2.07 2.03 0.33
Shell 3 0.73 0.93 1.90 0.63 0.87 1.26 0.74 0.72 1.20 1.00 0.40
Cylinder 4.11 4.31 4.40 4.69 5.04 5.09 3.46 3.44 9.20 4.86 1.73
Filter 29.82 27.79 24.46 29.79 26.84 25.94 27.60 28.02 21.72 26.89 2.58
Data referring to: 5.8.1 MDI formulation comparisons at 301 min'1
Ventolin™:
Experiment No.
Stage 1 2 3 Mean St Dev
AM 15.23 14.44 14.45 14.70 0.01
T+Bif 60.49 53.83 58.12 57.48 3.03
Shell 1 1.87 1.39 1.89 1.71 0.36
Shell 2 1.49 1.04 0.87 1.13 0.12
Shell 3 1.26 0.60 0.57 0.81 0.02
Shell 4 1.61 0.63 1.33 1.19 0.49
Shell 5 4.85 5.81 7.12 5.93 0.93
Bk Plate 0.55 0.65 0.68 0.63 0.02
Filter 12.64 21.62 14.98 16.41 4.70
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Evohaler™:
Can / experiment No.
Stage 1 2 3 Mean St Dev
AM 22.52 20.03 20.51 21.02 0.33
T+Bif 46.16 46.70 46.18 46.35 0.37
Shell 1 3.54 3.27 4.44 3.75 0.83
Shell 2 3.55 3.38 4.05 3.66 0.47
Shell 3 1.60 1.76 2.05 1.80 0.21
Shell 4 1.72 1.87 1.32 1.64 0.39
Shell 5 2.71 2.70 3.61 3.00 0.64
Bk Plate 1.74 1.80 1.76 1.77 0.03
Filter 16.46 18.49 16.08 17.01 1.71
Airomir™:
Experiment No
Stage 1 2 3 Mean St Dev
AM 27.88 30.53 31.45 29.95 0.65
T+Bif 36.76 31.62 34.26 34.21 1.87
Shell 1 1.27 0.96 0.66 0.96 0.21
Shell 2 1.18 0.78 0.66 0.87 0.09
Shell 3 0.49 0.47 1.36 0.77 0.62
Shell 4 1.35 1.07 1.03 1.15 0.03
Shell 5 4.38 4.12 4.58 4.36 0.32
Bk Plate 0.71 0.50 0.28 0.50 0.15
Filter 25.99 29.96 25.73 27.22 2.99
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Data referring to: 5.8.2 MDI formulation comparisons at 601 min'1
Ventolin™:
Experiment No.
Stage 1 2 3 Mean St Dev
AM 8.60 9.09 10.85 9.51 1.18
T+Bif 69.34 68.83 65.47 67.88 2.10
Shell 1 4.82 3.39 4.34 4.19 0.73
Shell 2 2.96 2.15 2.45 2.52 0.41
Shell 3 0.62 0.60 0.65 0.62 0.02
Shell 4 0.95 0.59 0.39 0.64 0.28
Shell 5 2.60 1.34 0.45 1.46 1.08
Bk Plate 1.33 1.30 1.11 1.24 0.12
Filter 8.79 12.70 14.30 11.93 2.84
Evohaler™:
Experiment No.
Stage 1 2 3 Mean St Dev
AM 9.53 11.94 16.39 12.62 3.48
T+Bif 70.77 70.05 55.45 65.42 8.64
Shell 1 3.24 4.50 8.25 5.33 2.61
Shell 2 2.86 3.59 6.57 4.34 1.97
Shell 3 0.94 1.05 2.22 1.40 0.71
Shell 4 0.92 0.57 0.80 0.76 0.18
Shell 5 5.23 1.86 0.89 2.66 2.28
Bk Plate 1.58 1.86 3.05 2.17 0.78
Filter 4.93 4.57 6.38 5.29 0.95
Airomir™:
Experiment No.
Stage 1 2 3 Mean St Dev
AM 19.22 18.94 22.39 20.19 1.91
T+Bif 52.70 53.33 53.34 53.12 0.36
Shell 1 5.83 2.84 4.85 4.50 1.53
Shell 2 3.52 1.92 3.14 2.86 0.83
Shell 3 0.67 3.65 0.56 1.62 1.75
Shell 4 0.51 3.85 0.28 1.55 2.00
Shell 5 1.84 3.59 2.54 2.66 0.88
Bk Plate 1.74 1.02 1.59 1.45 0.38
Filter 13.97 10.86 11.32 12.05 1.68
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Data referring to: 5.9.1 ACI data for Ventolin™ MDI formulation
Shot Numbers
5-15 16-25 26-35 36-45 46-55 56-65 Mean
AM 10.77 9.58 9.99 11.66 9.71 9.34 10.18
Throat 53.46 52.14 50.88 41.53 41.63 41.46 46.85
0 0.13 0.70 0.53 2.84 2.23 2.56 1.50
1 0.18 0.41 0.39 3.02 2.25 2.69 1.49
2 0.70 0.85 0.65 3.00 2.56 2.34 1.68
3 7.66 8.82 9.07 14.59 14.36 13.41 11.32
4 16.58 17.23 17.95 15.40 17.32 17.65 17.02
5 8.46 8.71 8.78 5.06 5.57 6.73 7.22
6 0.90 0.82 0.72 1.00 1.40 1.54 1.06
7 0.35 0.34 0.30 1.39 2.03 1.60 1.00
Filter 0.82 0.40 0.76 0.50 0.93 0.69 0.68
Data referring to: 5.9.2 ACI data for Airomir™ MDI formulation
Shot Numbers
6-15 16-25 26-35 36-45 46-55 56-65 Mean
AM 28.72 27.50 29.44 28.07 28.72 26.29 28.12
Throat 48.83 39.90 43.90 47.28 41.14 42.97 44.00
0 0.34 0.62 1.31 1.02 0.62 0.77 0.78
1 0.48 1.15 1.25 1.89 1.91 2.44 1.52
2 0.43 0.99 0.88 1.40 1.53 2.61 1.31
3 0.65 1.28 1.35 1.15 2.41 5.30 2.02
4 3.39 10.93 4.52 2.32 14.53 21.09 9.47
5 14.18 20.25 11.71 8.25 20.45 18.25 15.52
6 1.36 11.07 25.76 22.69 6.51 4.90 12.05
7 1.03 1.67 3.25 6.91 1.77 2.32 2.83
Filter 0.59 1.71 3.08 2.42 3.06 6.70 2.93
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Data referring to: 5.9.3 ACI data for Evohaler™ MDI formulation
Shot Numbers
6-15 16-25 26-35 Mean
AM 17.1 13.3 14.3 14.9
Throat 39.4 32.5 37.8 36.6
0 6.6 9.5 8.2 8.1
1 5.1 7.5 6.9 6.5
2 5.2 8.1 5.8 6.4
3 13.1 16.3 14.2 14.6
4 8.2 7.2 7.1 7.5
5 2.1 1.4 1.7 1.7
6 0.8 1.0 0.9 0.9
7 1.9 2.4 2.2 2.2
Filter 0.6 0.7 0.8 0.7
Data referring to: 5.9.4 ACI data for Bricanyl™ MDI formulation
Shot Numbers
6-15 16-25 26-35 Mean
AM 7.49 10.19 17.21 11.63
Throat 47.90 46.18 51.18 48.42
0 1.62 2.53 2.66 2.27
1 4.74 4.66 3.01 4.14
2 9.09 5.26 1.95 5.43
3 6.75 12.50 4.06 7.77
4 11.79 10.66 7.69 10.04
5 6.99 4.61 8.05 6.55
6 2.74 2.06 0.27 1.69
7 0.50 0.77 3.44 1.57
Filter 0.41 0.57 0.48 0.49
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Data referring to: 5.10 Bifurcation re-manufacture
Old Bifurcation Ventolin™:
Experiment
1 2 3 Mean
AM 15.23 14.44 14.45 14.70
Throat 60.49 53.83 58.12 57.48
0 1.87 1.39 1.89 1.71
1 1.49 1.04 0.87 1.13
2 1.2d 0.60 0.57 0.81
3 1.61 0.63 1.33 1.19
4 4.85 5.81 7.12 5.93
5 0.55 0.65 0.68 0.63
6 12.64 21.62 14.98 16.41
7 15.23 14.44 14.45 14.70
Filter 60.49 53.83 58.12 57.48
New bifurcation Ventolin™:
Experiment
1 2 3 Mean
AM 17.08 17.65 16.47 17.07
Throat 57.72 55.71 56.71 56.71
0 4.94 5.48 5.26 5.23
1 2.87 3.07 3.38 3.10
2 0.87 0.61 1.06 0.85
3 0.87 0.59 1.06 0.84
4 1.85 4.66 1.90 2.80
5 1.56 1.19 1.60 1.45
6 12.25 11.04 12.55 11.94
7 17.08 17.65 16.47 17.07




1 2 3 Mean
AM 12.82 13.07 12.77 12.89
Throat 66.49 69.25 71.69 69.14
0 5.37 6.09 4.92 5.46
1 4.93 4.56 3.58 4.36
2 1.19 0.69 0.52 0.80
3 0.93 0.79 0.40 0.71
4 1.36 1.08 2.72 1.72
5 1.95 1.64 0.83 1.48
6 4.94 2.84 2.56 3.45
7 12.82 13.07 12.77 12.89
Filter 66.49 69.25 71.69 69.14
New bifurcation Bricanyl™:
Experiment
1 2 3 Mean
AM 14.32 12.30 13.60 13.40
Throat 61.52 65.13 64.42 63.69
0 5.93 9.14 8.37 7.81
1 5.44 6.44 5.93 5.94
2 1.21 1.19 1.11 1.17
3 0.85 0.49 0.39 0.58
4 1.88 0.83 0.82 1.17
5 2.30 0.94 1.81 1.68
6 6.57 3.54 3.55 4.55
7 14.32 12.30 13.60 13.40
Filter 61.52 65.13 64.42 63.69
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Data referring to: 5.11.1
SML Bricanyl™ Turbuhaler™
Experiment No.
Stage 1 2 3 4 5 6 Mean St Dev
AM 8.67 11.16 9.16 13.31 5.16 3.82 8.55 3.57
T+Bif 64.93 63.89 72.54 60.32 75.19 72.60 68.25 5.97
Shell 1 15.84 13.50 10.10 12.51 11.41 13.63 12.83 1.99
Shell 2 4.56 4.73 3.75 5.32 4.09 4.62 4.51 0.54
Shell 3 1.72 2.07 1.22 3.17 1.64 1.45 1.88 0.69
Shell 4 0.68 0.58 0.83 0.61 0.34 0.49 0.59 0.16
Shell 5 1.08 0.24 0.69 0.48 0.39 0.29 0.53 0.31
Bk Plate 1.44 2.47 0.62 3.31 0.93 1.98 1.79 1.00
Filter 1.08 1.35 1.10 0.97 0.85 1.12 1.08 0.17
ACI Bricanyl™ Turbuhaler™
Experiment No.
Stage 1 2 3 4 5 Mean St. Dev
AM 28.72 27.50 29.44 28.07 28.72 26.29 28.12
Throat 48.83 39.90 43.90 47.28 41.14 42.97 44.00
0 0.34 0.62 1.31 1.02 0.62 0.77 0.78
1 0.48 1.15 1.25 1.89 1.91 2.44 1.52
2 0.43 0.99 0.88 1.40 1.53 2.61 1.31
3 0.65 1.28 1.35 1.15 2.41 5.30 2.02
4 3.39 10.93 4.52 2.32 14.53 21.09 9.47
5 14.18 20.25 11.71 8.25 20.45 18.25 15.52
6 1.36 11.07 25.76 22.69 6.51 4.90 12.05
7 1.03 1.67 3.25 6.91 1.77 2.32 2.83
Filter 0.59 1.71 3.08 2.42 3.06 6.70 2.93
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Data referring to: 5.11.2
SML Ventolin™ Diskhaler™:
Experiment No.
Stage 1 2 3 4 5 6 Mean St Dev
AM 40.07 68.14 50.94 35.80 48.54 45.73 48.20 9.45
T+Bif 38.72 19.91 31.47 44.77 33.46 31.71 33.34 8.32
Shell 1 5.68 3.33 5.17 5.03 4.93 5.52 4.94 0.84
Shell 2 6.80 3.51 5.01 5.24 5.55 7.78 5.65 1.48
Shell 3 1.69 0.79 1.26 1.38 1.44 2.06 1.44 0.43
Shell 4 1.07 0.56 0.67 0.79 0.73 0.98 0.80 0.19
Shell 5 0.03 0.00 0.16 0.20 0.19 0.18 0.13 0.09
Bk Plate 2.29 1.07 2.11 2.29 2.43 2.44 2.10 0.52
Filter 3.64 2.70 3.21 4.49 2.72 3.59 3.39 0.68
ACI Ventolin™ Diskhaler™
Experiment No.
Stage 1 2 3 4 5 Mean St. Dev
AM 35.58 33.86 31.01 36.40 49.45 37.26 7.12
Throat 28.91 26.57 27.94 33.25 19.48 27.23 5.00
0 9.64 11.41 14.91 6.63 9.08 10.33 3.08
1 4.91 5.52 4.61 3.47 3.59 4.42 0.88
2 2.70 2.54 2.66 2.52 1.60 2.40 0.46
3 4.61 4.75 2.73 4.65 2.86 3.92 1.03
4 6.41 7.45 9.50 7.33 5.43 7.23 1.51
5 5.23 5.79 3.89 3.15 6.61 4.94 1.41
6 1.13 1.26 1.20 1.29 1.18 1.21 0.07
7 0.46 0.44 1.09 0.93 0.45 0.67 0.31
Filter 0.41 0.40 0.46 0.37 0.28 0.38 0.07
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Data referring to: 5.12
Ventolin™ MDI @101 min'1
Ex periment No.
Stage 1 2 3 Mean St Dev
AM 14.27 15.54 15.83 15.21 0.83
T+Bif 53.89 55.99 61.97 57.28 4.19
Shell 1 5.64 3.56 2.11 3.77 1.77
Shell 2 2.96 1.89 1.36 2.07 0.82
Shell 3 0.74 0.76 0.45 0.65 0.18
Shell 4 0.58 0.48 0.60 0.55 0.06
Shell 5 0.69 0.51 0.45 0.55 0.13
Bk Plate 1.21 0.98 0.68 0.96 0.27
Filter 20.01 20.31 16.55 18.96 2.09
Ventolin™ MDI @ 30 1 min'1
Experiment No.
Stage 1 2 3 Mean St Dev
AM 14.88 14.76 14.69 14.78 0.09
T+Bif 65.52 66.88 66.86 66.42 0.78
Shell 1 7.41 6.83 5.56 6.60 0.94
Shell 2 3.81 3.52 2.70 3.34 0.57
Shell 3 0.92 0.86 0.82 0.87 0.05
Shell 4 0.60 0.54 0.68 0.61 0.07
Shell 5 0.59 0.64 0.96 0.73 0.20
Bk Plate 1.37 1.86 1.44 1.56 0.27
Filter 4.90 4.10 6.29 5.10 1.11
Ventolin™ MDI @ 55 1 min'1
Ex periment No.
Stage 1 2 3 Mean St Dev
AM 12.99 15.54 12.01 13.51 1.82
T+Bif 52.55 53.84 59.70 55.36 3.81
Shell 1 11.44 8.49 7.95 9.30 1.88
Shell 2 4.75 4.42 3.68 4.28 0.55
Shell 3 0.88 1.05 0.77 0.90 0.14
Shell 4 0.40 0.65 0.38 0.47 0.15
Shell 5 0.57 0.82 0.49 0.62 0.17
Bk Plate 2.03 1.95 1.36 1.78 0.37
Filter 14.39 13.24 13.66 13.76 0.58
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Appendix B
Study on the SML using Ventolin™ MDI with or without a spacer device 
(Volumatic™)
Introduction
The SML was used to analyse the deposition profile of a Ventolin™ MDI when used 
with a Volumatic™ spacer device and used alone. Spacers are devices designed to ‘hold’ 
the aerosol cloud reducing the velocity and momentum of the particles and preventing 
impaction of the drug particles on the back of the throat. Spacers are particularly useful 
for the elderly, children and patients who experience difficulty coordinating actuation of 
a MDI with breathing.
Methods
The SML was assembled as described in section 5.4.2. The model was used to test 
Ventolin™ without or with the Volumatic™ spacer device. The flow rate was set to 30 1 
min'1 and the timer was set to 10 seconds ten actuations were made during each 
experiment. Three MDIs were used during the experiment however as Ventolin™ is a 
relatively reproducible formulation the intra-batch differences were ignored and a new 
can began after 5 experiments. Each new can was primed by actuating 5 shots to waste.
A series of 14 experiments were carried out n=7 with the spacer in position and n=7 
when no spacer was used.
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Ventolin: Lot: 10467848 Exp: 10/01 
Volumatic® spacer device: Lot: 10c417119
The SML was washed according to section 5.4.5 the spacer was washed and analysed 
last. The spacer was washed using the same solvent for analysis. After washing for 
analysis the spacer was rinsed using clean tap water then methanol and left to dry 
naturally on the bench. To prevent accidental adding of an electrostatic charge the spacer 
was not dried using a towel or an air stream.
Results and Discussion
The graph shown in figure A2.1 clearly displays the difference the spacer device makes 
to the deposition of drug in the throat region. When the spacer was not used over 40% of 
the drug deposited in the throat region. When the spacer device was used this went down 
to 2%. The spacer device retained 36% of the drug. The remaining drug in the spacer 
device although we cannot say if  it is in fact of the correct size range, which would have 
impacted on the throat, is of the correct proportion.
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Figure Bl. Graph showing percentage drug recovered for each stage o f  the SML and 





>  30 H o01 
01
a)
3 20  -
10 -
TB
E m i  Ventolin™




The results were analysed using one-way Analysis o f  Variance and it was found that the 
only significant difference seen when using the MDI alone or when using the spacer and 
the MDI together was in the Throat and bifurcation (P<  0.05). Although the mean value 
o f  drug deposited in the filter increased when the spacer device was used the difference 
was not found to be significant (P=0.626). A similar result for deposition in the mouth 
and throat was found in vivo (p <0.05, 2-tailed student t-test) when analysing the 
pulmonary deposition o f  radiolabelled Fluticasone delivered using an MDI (Berridge et 
al 2000).
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Unfortunately the total drug recovered in the first three experiments was below 800pg 
however even though these results cannot be considered to be reliable it is clear that the 
distinction between spacer and no spacer use is valid.
A comparison of the studies using spacers is summarised in Figure AX. The results of 
these studies display deposition in the oropharynx, lung and retention in the spacer where 
appropriate.
Figure B2 Comparison of spacer studies performed for MDI use.






Newman (1984) MDI 80.9 8.7
MDI + Spacer 16.5 20.9 56
Hassanally (1987) MDI 76.2 10.6
MDI + Spacer 1.5 21.2 55.7




Mattys (1988) MDI 64 26
MDI + Spacer 9.5 34
Newman (1991) MDI 78.2 12.8
MDI + Spacer 9.8 23.8
The difference seen in the studies performed and summarised in Figure AX and the study 
presented here may be attributed to electrostatic effects.
Conclusion
It has been demonstrated that the use of a Volumatic™ spacer device with a Ventolin™ 
MDI reduces drug deposition in the throat and bifurcation of the SML. The evidence 
collected here does not demonstrate that an increase in lung deposition occurs with spacer
202
use. This study was performed when the first bifurcation was in use so it would be of 




SML diagrams from solid modelling package courtesy of Jeff Ward
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